<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">99438</article-id><article-id pub-id-type="doi">10.7554/eLife.99438</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99438.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Mitochondrial protein carboxyl-terminal alanine-threonine tailing promotes human glioblastoma growth by regulating mitochondrial function</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Bei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cai</surname><given-names>Ting</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Reddy</surname><given-names>Esha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yuanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mondal</surname><given-names>Isha</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yinglu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gbufor</surname><given-names>Adaeze Scholastical</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jerry</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Yawei</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Raymond</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6352-0642</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Winson S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lu</surname><given-names>Rongze Olivia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1600-9299</contrib-id><email>rongze.lu@ucsf.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Zhihao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3080-5769</contrib-id><email>zhihaowu@smu.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042tdr378</institution-id><institution>Department of Biological Sciences, Dedman College of Humanities and Sciences, Southern Methodist University</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Neurological Surgery, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037s24f05</institution-id><institution>Department of Biological Sciences, Clemson University</institution></institution-wrap><addr-line><named-content content-type="city">Clemson</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037s24f05</institution-id><institution>Center for Human Genetics, Clemson University</institution></institution-wrap><addr-line><named-content content-type="city">Greenwood</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sugimura</surname><given-names>Rio</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>The University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kornmann</surname><given-names>Benoit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>McCombs School of Business, University of Texas at Austin, Austin, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>01</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP99438</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-05-16"><day>16</day><month>05</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-05-18"><day>18</day><month>05</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.15.594447"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-02"><day>02</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99438.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-09-30"><day>30</day><month>09</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99438.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-12-10"><day>10</day><month>12</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99438.3"/></event></pub-history><permissions><copyright-statement>© 2024, Zhang, Cai et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zhang, Cai et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-99438-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-99438-figures-v1.pdf"/><abstract><p>The rapid and sustained proliferation of cancer cells necessitates increased protein production, which, along with their disrupted metabolism, elevates the likelihood of translation errors. Ribosome-associated quality control (RQC), a recently identified mechanism, mitigates ribosome collisions resulting from frequent translation stalls. However, the precise pathophysiological role of the RQC pathway in oncogenesis remains ambiguous. Our research centered on the pathogenic implications of mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing), a specific RQC response to translational arrest on the outer mitochondrial membrane, in human glioblastoma multiforme (GBM). The presence of msiCAT-tailed mitochondrial proteins was observed commonly in glioblastoma stem cells (GSCs). The exogenous introduction of the mitochondrial ATP synthase F1 subunit alpha (ATP5α) protein, accompanied by artificial CAT-tail mimicking sequences, enhanced mitochondrial membrane potential (ΔΨm) and inhibited the formation of the mitochondrial permeability transition pore (MPTP). These alterations in mitochondrial characteristics provided resistance to staurosporine (STS)-induced apoptosis in GBM cells. Consequently, msiCAT-tailing can foster cell survival and migration, whereas blocking msiCAT-tailing via genetic or pharmacological intervention can impede GBM cell overgrowth.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>glioblastoma</kwd><kwd>ribosome-associated quality control</kwd><kwd>carboxyl-terminal alanine and threonine tailing</kwd><kwd>mitochondria</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q48ey07</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM150190</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhihao</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s5ya894</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01NS126501</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Rongze Olivia</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0003xa228</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP210068</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Rongze Olivia</given-names></name><name><surname>Wu</surname><given-names>Zhihao</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042tdr378</institution-id><institution>Southern Methodist University</institution></institution-wrap></funding-source><award-id>Dedman College Dean's Research Council grant</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhihao</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>South Carolina Alzheimer's Disease Research Center</institution></institution-wrap></funding-source><award-id>ARDC Pilot Grant</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Qing</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The carboxyl-terminal alanine-threonine-tailed protein ATP5α helps glioblastoma mitochondria maintain a high membrane potential and keep the permeability transition pore closed, thereby promoting tumor growth and increasing resistance to apoptosis.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Proteins are vital to biological processes, and their overproduction is particularly crucial for rapidly proliferating cells, such as those found in cancer. To cope with this increased demand, cancer cells extensively reform the initiation, elongation, and termination phases of their protein synthesis (<xref ref-type="bibr" rid="bib53">Robichaud et al., 2019</xref>). However, heightened protein translation elevates the chance of errors (<xref ref-type="bibr" rid="bib20">Dever and Green, 2012</xref>). Coupled with metabolic perturbations such as energy fluctuations and redox imbalances, the capacity to address disruptions during translation becomes indispensable. Ribosome-associated quality control (RQC) is a recently discovered suite of rescue mechanisms in eukaryotes that detect and resolve stalled, decelerated, or collided ribosomes during translation elongation or termination (<xref ref-type="bibr" rid="bib39">Kim and Zaher, 2022</xref>; <xref ref-type="bibr" rid="bib9">Brandman et al., 2012</xref>).</p><p>RQC is a multistep process initiated by the ZNF598/RACK1 complex, which recognizes the distinctive 40S-40S interface on collided ribosomes, triggering the ubiquitination of specific 40S subunit proteins (<xref ref-type="bibr" rid="bib33">Juszkiewicz and Hegde, 2017</xref>; <xref ref-type="bibr" rid="bib63">Sundaramoorthy et al., 2017</xref>). Subsequently, the ASC-1 complex separates the leading ribosome (<xref ref-type="bibr" rid="bib29">Hashimoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Juszkiewicz et al., 2020</xref>). Following this, events that transpire include: ribosomal subunit dissociation and recycling (<xref ref-type="bibr" rid="bib57">Shao and Hegde, 2014</xref>), modification of the nascent peptide chains by C-terminal alanine and threonine addition (CAT-tailing) (<xref ref-type="bibr" rid="bib58">Shen et al., 2015</xref>), release of CAT-tailed products from the 60S subunits by ANKZF1/VMS1 (<xref ref-type="bibr" rid="bib66">Verma et al., 2018</xref>), and degradation of aberrant peptides by the Ltn1/VCP/NEMF complex (<xref ref-type="bibr" rid="bib9">Brandman et al., 2012</xref>). The functional significance of CAT-tailed proteins produced during RQC remains incompletely understood. They may facilitate Ltn1-mediated ubiquitination (<xref ref-type="bibr" rid="bib41">Kostova et al., 2017</xref>) and promote the degradation of defective nascent peptides by exposing lysine residues (<xref ref-type="bibr" rid="bib46">Lytvynenko et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Sitron et al., 2020</xref>). Nonetheless, they are also prone to forming detergent-insoluble aggregates (<xref ref-type="bibr" rid="bib14">Choe et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Yonashiro et al., 2016</xref>). Furthermore, contingent upon the nature of the original protein and its subcellular location, CAT-tailed proteins might possess specific, albeit currently unclear, functions. Notably, CAT-tailed proteins have been implicated in the pathogenesis of several neurodegenerative diseases, indicating a significant role in their progression (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Rimal et al., 2021</xref>).</p><p>Cancerous cells exhibit increased translation irregularities, including stop codon readthrough (<xref ref-type="bibr" rid="bib68">Wang and Wang, 2021</xref>), frame-shifting (<xref ref-type="bibr" rid="bib11">Champagne et al., 2021</xref>), and oxidative stress-induced ribosomal arrest (<xref ref-type="bibr" rid="bib54">Rubio et al., 2021</xref>), which suggests a potential role for the RQC pathway. While CAT-tail modification of mitochondrial proteins due to compromised RQC has been noted in HeLa cells, the mechanistic involvement of RQC factors in cancer biology remains largely unexplored (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>). Notably, the expression profile of various RQC factors (e.g. ASCC3, ABCE1, ANKZF1, and VCP) is dysregulated in cancer (<xref ref-type="bibr" rid="bib19">Dango et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Gao et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Costantini et al., 2021</xref>). Interestingly, RQC factors can display opposing functions in cancer development and suppression depending on specific circumstances, with some factors like ABCE1, ASCC3, and VCP suppressing cancer cell growth upon downregulation (<xref ref-type="bibr" rid="bib19">Dango et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Gao et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Costantini et al., 2021</xref>), while others like NEMF/Clbn and ZNF598 may promote it upon inhibition (<xref ref-type="bibr" rid="bib6">Bi et al., 2005</xref>; <xref ref-type="bibr" rid="bib72">Yang and Gupta, 2018</xref>). This suggests a nuanced, context-dependent role for RQC components in cancer cells, influenced by both genetic and environmental factors. A recent study investigated the mechanism of ANKZF1 in mitochondrial proteostasis and its impact on glioblastoma multiforme (GBM) progression (<xref ref-type="bibr" rid="bib43">Li et al., 2024</xref>). However, this study employed a nonphysiological mitochondria-targeted GFP to induce matrix proteotoxicity, leaving the role of endogenous mitochondrial proteins in this process ambiguous.</p><p>Mitochondrial stress leads to co-translational import anomalies, eliciting widespread CAT-tailing (mitochondrial stress-induced CAT-tail or msiCAT-tail) of nuclear-encoded mitochondrial proteins, including C-I30 (Complex-I 30 kDa subunit protein, NDUS3) (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Gehrke et al., 2015</xref>). The functional ramifications of these msiCAT-tailed proteins in mitochondrial biology remain poorly elucidated. Given that CAT-tailing imparts new properties to proteins, it may contribute to the distinctive features of cancer cell mitochondria, such as hyperpolarization (<xref ref-type="bibr" rid="bib22">Forrest, 2015</xref>; <xref ref-type="bibr" rid="bib59">Shi et al., 2019</xref>) and resistance to drug-induced apoptosis linked to a high mitochondrial membrane potential (Δψm) (<xref ref-type="bibr" rid="bib27">Guièze et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Ramamoorthy et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Heerdt et al., 2006</xref>). This membrane potential across the inner membrane of mitochondria, essential for ATP production by OXPHOS, is sustained by the electron transport chain (Complexes I to IV), which pumps protons (H<sup>+</sup>) into the intermembrane space (<xref ref-type="bibr" rid="bib76">Zorova et al., 2018</xref>), and ATP synthase (Complex V), which leverages this gradient (<xref ref-type="bibr" rid="bib47">Maria, 2020</xref>). While numerous malignant cells exhibit reduced OXPHOS despite high energy demands (<xref ref-type="bibr" rid="bib44">Liberti and Locasale, 2016</xref>), the mechanisms by which they maintain or elevate ΔΨm remain an unresolved question (<xref ref-type="bibr" rid="bib22">Forrest, 2015</xref>).</p><p>In this study, we investigated msiCAT-tailing modification on the mitochondrial ATP synthase F1 subunit alpha (ATP5α). We discerned that msiCAT-tailed ATP5α is present in GBM. The mimic short-tailed ATP5α (ATP5α-AT3 in subsequent studies) can integrate into the ATP synthase, leading to an augmented ΔΨm and attenuated mitochondrial permeability transition pore (MPTP) assembly and opening. Consequently, msiCAT-tailed ATP5α enhances GBM cell resistance to programmed cell death induced by staurosporine (STS) and temozolomide (TMZ), thereby fostering cancer cell survival, proliferation, and migration. Conversely, impeding msiCAT-tailing diminishes cancer cell growth and resensitizes GBM cells to apoptosis. Our findings underscore the involvement of CAT-tailed mitochondrial proteins in tumorigenesis and emphasize the significance of the RQC pathway in oncobiology. These outcomes suggest that components and products of the RQC pathway may offer promising therapeutic targets for GBM.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Presence of msiCAT-tailed proteins in glioblastoma cells</title><p>While dysregulation of individual RQC factors is documented across various cancers (e.g. adenocarcinoma, non-small cell lung, prostate, and colon carcinomas), a comprehensive analysis of the RQC pathway in glioblastoma (GBM) has been lacking (<xref ref-type="bibr" rid="bib19">Dango et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Gao et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Costantini et al., 2021</xref>). Our analysis of transcriptomic data from a cohort of 153 GBM patients and 206 healthy controls, sourced from public datasets, revealed significantly elevated expression (logFC (fold change)&gt;1; adj.P.Val &lt;0.001) of RQC pathway genes, such as <italic>ABCE1</italic>, <italic>ASCC1-3</italic>, <italic>RACK1</italic>, and <italic>VCP,</italic> in GBM cells (<xref ref-type="bibr" rid="bib64">Varn et al., 2022</xref>). Conversely, <italic>ANKZF1</italic> was significantly downregulated (logFC = –0.43, adj.P.Val=0.0005) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). The expression change in these genes implies activation of the RQC pathway and potential accumulation of CAT-tailed proteins in GBM. Mitochondrial stress-induced protein mitochondrial Complex-I 30 kDa (C-I 30, also known as NDUS3), an endogenous RQC substrate with msiCAT-tails, was previously identified in HeLa cells (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>). Examination of patient-derived glioblastoma stem cells (GSCs) and normal neural stem cells (NSCs) revealed that GSCs, unlike NSCs, exhibited several msiCAT-tailed mitochondrial proteins, including NDUS3, COX4 (cytochrome <italic>c</italic> oxidase subunit 4), and ATP5α (ATP synthase F1 subunit alpha). Consistent with the detection of these msiCAT-tailing signals, increased NEMF (Nuclear Export Mediator Factor) levels (<xref ref-type="bibr" rid="bib58">Shen et al., 2015</xref>) and decreased ANKZF1 (Ankyrin Repeat and Zinc-finger Peptidyl tRNA Hydrolase 1) expression (<xref ref-type="bibr" rid="bib66">Verma et al., 2018</xref>) were observed in patient-derived GSCs (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), further indicative of enhanced CAT-tailing activation, mirroring bioinformatics findings in GBM samples. A murine GBM model exhibited analogous RQC pathway alterations, with increased NEMF and decreased ANKZF1 expression in transplanted SB28 gliomas compared to normal brain tissue (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Evidence for mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) on mitochondrial proteins in glioblastoma multiforme (GBM) cells.</title><p>(<bold>A</bold>) Ribosome-associated quality control (RQC) gene expression levels in GBM tumor tissues (n=153) compared to normal brain tissues (n=206) (unpaired Student’s t-test; *, logFC (fold change)&gt;1; adj.P.Val&lt;0.001). (<bold>B</bold>) Western blot analysis of msiCAT-tailed mitochondrial proteins and RQC factors in patient-derived glioblastoma stem cells (GSCs) and control neural stem cells (NSCs), using ACTIN as the loading control. Red arrowheads indicate short CAT-tailed mitochondrial proteins; ‘short’ and ‘long’ refer to exposure time; the red numbers represent fold changes compared to controls (NSC). (<bold>C</bold>) Western blot of 5×FLAG-tagged β-globin reporter proteins in GBM and control cells, showing more CAT-tailed proteins in GBM cells, using ACTIN as the loading control. The red numbers represent fold changes compared to controls (NHA without any treatment); the purple numbers represent the ratio of red (CAT-tailed) to green (non-CAT-tailed) sections. (<bold>D</bold>) Western blot of overexpressed ATP5α-AT3 and ATP5α-AT20 in GBM and control cells, using GAPDH as the loading control; arrowheads indicate endogenous ATP5α, ATP5α-AT3, ATP5α-AT20, and oligomers/aggregates of msiCAT-tailed ATP5α proteins. The purple numbers represent the ratio of red (exogenous) to green (endogenous) sections. (<bold>E</bold>) Immunofluorescence staining shows endogenous ATP5α protein aggregates in GBM cells, with TOM20 (red) as a mitochondrial marker. White arrows indicate ATP5α protein aggregates. (<bold>F</bold>) Quantification of E (n=3; chi-squared test; ***, p&lt;0.001; ****, p&lt;0.0001); the total number of cells counted is indicated in the columns.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1">Figure 1B, C, and D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig1">Figure 1B, C, and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig1">Figure 1A, F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Ribosome-associated quality control (RQC) pathway activity in glioblastoma multiforme (GBM) cells.</title><p>(<bold>A</bold>) Immunofluorescence staining shows elevated NEMF and reduced ANKZF1 endogenous protein levels in the tumor tissue of the GBM mouse model compared to wild-type brain tissue. Tumor identification is indicated by GFP (green). (<bold>B</bold>) Quantification of A (n=3; unpaired Student’s t-test; ****, p&lt;0.0001). (<bold>C</bold>) Western blot analysis of select RQC factors in control cell lines (SVG, NHA) and GBM cell lines (SF268, GSC827), using ACTIN as the loading control. Red numbers represent fold changes in protein levels relative to controls (SVG).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig1-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>AT repeat sequences mimicking CAT-tails induce protein aggregates in cells.</title><p>(<bold>A</bold>) Western blot analysis of ATP5α in glioblastoma stem cell (GSC) and NHA cells, using GAPDH as the loading control. The purple arrowhead indicates the modified ATP5α form; ‘short’ and ‘long’ refer to exposure time. Red numbers represent fold changes in protein levels relative to controls (the leftmost bands); purple numbers represent fold changes in protein levels of the modified ATP5α form relative to the control (the leftmost band) in the GSC long exposure blots. (<bold>B</bold>) Western blot analysis of Flag-tagged ATP5α in GSC and control cells, using ACTIN as the loading control. The red arrowhead indicates the modified Flag-ATP5α form. (<bold>C</bold>) Immunofluorescence staining shows that Flag-tagged ATP5α-AT3 and ATP5α-AT20 (green) form aggregates in glioblastoma multiforme (GBM) and control cells, using TOM20 (red) as a mitochondrial marker. (<bold>D</bold>) Quantification of C (n=3; chi-squared test; ***, p&lt;0.001; ****, p&lt;0.0001); the total number of cells counted is indicated in the columns. (<bold>E</bold>) Western blot of Flag-tagged ATP5α-GS3 and ATP5α-GS20 in GBM cells, using ACTIN as the loading control. (<bold>F</bold>) Immunofluorescence staining shows that Flag-tagged ATP5α-GS3 and ATP5α-GS20 (green) do not form aggregates in GBM cells, using TOM20 (red) as a mitochondrial marker. (<bold>G</bold>) Quantification of F (n=3; chi-squared test; ns, not significant); the total number of cells counted is indicated in the columns.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B, and E</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B, and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig1-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata3"><label>Figure 1—figure supplement 2—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D, G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig1-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Aggregation of CAT-tailed mitochondrial proteins observed in vivo.</title><p>(<bold>A</bold>) Immunofluorescence staining shows that endogenous NDUS3 protein aggregates in glioblastoma multiforme (GBM) cells, with TOM20 (red) as a mitochondrial marker. White arrows indicate NUDS3 protein aggregates. (<bold>B</bold>) Quantification of A (n=3; chi-squared test; *, p&lt;0.05); the total number of cells counted is indicated in the columns. (<bold>C</bold>) Immunofluorescence staining reveals that endogenous ATP5α protein forms aggregates in tumor tissue from the GBM mouse model, but not in wild-type brain tissue, using TOM20 (blue) as a mitochondrial marker. Tumor identification is indicated by GFP (green). White arrowheads indicate ATP5α (red) aggregates. Yellow lines indicate the regions selected for intensity analysis in (<bold>D</bold>). (<bold>D</bold>) Fluorescence intensity profiles show the signals of ATP5α (red) and TOM20 (blue) in wild-type and tumor tissues. Black arrows indicate ATP5α aggregates located outside of mitochondria. (<bold>E</bold>) Quantification of C (n=3; chi-squared test; ****, p&lt;0.0001); the total number of cells counted is indicated in the columns.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B, D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig1-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig1-figsupp3-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Differential expression analysis of ribosome-associated quality control (RQC) genes in glioblastoma multiforme (GBM) patients compared to healthy controls.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">logFC</th><th align="left" valign="bottom">AveExpr</th><th align="left" valign="bottom">t</th><th align="left" valign="bottom">P.Value</th><th align="left" valign="bottom">adj.P.Val</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>RACK1</italic></td><td align="char" char="." valign="bottom">2.224548565</td><td align="char" char="." valign="bottom">9.048113333</td><td align="char" char="." valign="bottom">19.24641934</td><td align="char" char="hyphen" valign="bottom">2.62E-57</td><td align="char" char="hyphen" valign="bottom">6.69E-56</td></tr><tr><td align="left" valign="bottom"><italic>ASCC3</italic></td><td align="char" char="." valign="bottom">1.738216567</td><td align="char" char="." valign="bottom">2.717246389</td><td align="char" char="." valign="bottom">19.27211713</td><td align="char" char="hyphen" valign="bottom">2.05E-57</td><td align="char" char="hyphen" valign="bottom">5.27E-56</td></tr><tr><td align="left" valign="bottom"><italic>ASCC1</italic></td><td align="char" char="." valign="bottom">1.689584768</td><td align="char" char="." valign="bottom">4.257915556</td><td align="char" char="." valign="bottom">17.8774401</td><td align="char" char="hyphen" valign="bottom">1.20E-51</td><td align="char" char="hyphen" valign="bottom">2.18E-50</td></tr><tr><td align="left" valign="bottom"><italic>ASCC2</italic></td><td align="char" char="." valign="bottom">1.471467207</td><td align="char" char="." valign="bottom">4.153399167</td><td align="char" char="." valign="bottom">15.9118075</td><td align="char" char="hyphen" valign="bottom">1.43E-43</td><td align="char" char="hyphen" valign="bottom">1.68E-42</td></tr><tr><td align="left" valign="bottom"><italic>ABCE1</italic></td><td align="char" char="." valign="bottom">1.32826428</td><td align="char" char="." valign="bottom">3.81695</td><td align="char" char="." valign="bottom">13.79248369</td><td align="char" char="hyphen" valign="bottom">4.69E-35</td><td align="char" char="hyphen" valign="bottom">3.60E-34</td></tr><tr><td align="left" valign="bottom"><italic>VCP</italic></td><td align="char" char="." valign="bottom">1.050066326</td><td align="char" char="." valign="bottom">6.321021667</td><td align="char" char="." valign="bottom">9.828944092</td><td align="char" char="hyphen" valign="bottom">2.33E-20</td><td align="char" char="hyphen" valign="bottom">9.31E-20</td></tr><tr><td align="left" valign="bottom"><italic>GIGYF2</italic></td><td align="char" char="." valign="bottom">0.985695112</td><td align="char" char="." valign="bottom">3.786421389</td><td align="char" char="." valign="bottom">10.25440005</td><td align="char" char="hyphen" valign="bottom">8.00E-22</td><td align="char" char="hyphen" valign="bottom">3.41E-21</td></tr><tr><td align="left" valign="bottom"><italic>MAP3K20</italic></td><td align="char" char="." valign="bottom">0.962218073</td><td align="char" char="." valign="bottom">1.863793889</td><td align="char" char="." valign="bottom">8.711292467</td><td align="char" char="hyphen" valign="bottom">1.10E-16</td><td align="char" char="hyphen" valign="bottom">3.75E-16</td></tr><tr><td align="left" valign="bottom"><italic>PELO</italic></td><td align="char" char="." valign="bottom">0.92860628</td><td align="char" char="." valign="bottom">2.2885625</td><td align="char" char="." valign="bottom">10.60122263</td><td align="char" char="hyphen" valign="bottom">4.85E-23</td><td align="char" char="hyphen" valign="bottom">2.18E-22</td></tr><tr><td align="left" valign="bottom"><italic>KLHDC10</italic></td><td align="char" char="." valign="bottom">0.854921284</td><td align="char" char="." valign="bottom">3.492322222</td><td align="char" char="." valign="bottom">9.064976509</td><td align="char" char="hyphen" valign="bottom">8.08E-18</td><td align="char" char="hyphen" valign="bottom">2.88E-17</td></tr><tr><td align="left" valign="bottom"><italic>EDF1</italic></td><td align="char" char="." valign="bottom">0.82091202</td><td align="char" char="." valign="bottom">8.444505</td><td align="char" char="." valign="bottom">7.278600017</td><td align="char" char="hyphen" valign="bottom">2.12E-12</td><td align="char" char="hyphen" valign="bottom">5.94E-12</td></tr><tr><td align="left" valign="bottom"><italic>XRN1</italic></td><td align="char" char="." valign="bottom">0.809119864</td><td align="char" char="." valign="bottom">1.518371111</td><td align="char" char="." valign="bottom">8.54020086</td><td align="char" char="hyphen" valign="bottom">3.80E-16</td><td align="char" char="hyphen" valign="bottom">1.26E-15</td></tr><tr><td align="left" valign="bottom"><italic>LTN1</italic></td><td align="char" char="." valign="bottom">0.786409776</td><td align="char" char="." valign="bottom">1.9716</td><td align="char" char="." valign="bottom">9.962815742</td><td align="char" char="hyphen" valign="bottom">8.14E-21</td><td align="char" char="hyphen" valign="bottom">3.32E-20</td></tr><tr><td align="left" valign="bottom"><italic>MKRN1</italic></td><td align="char" char="." valign="bottom">0.769369764</td><td align="char" char="." valign="bottom">5.745359444</td><td align="char" char="." valign="bottom">7.400071791</td><td align="char" char="hyphen" valign="bottom">9.65E-13</td><td align="char" char="hyphen" valign="bottom">2.74E-12</td></tr><tr><td align="left" valign="bottom"><italic>RCHY1</italic></td><td align="char" char="." valign="bottom">0.652647968</td><td align="char" char="." valign="bottom">4.276126111</td><td align="char" char="." valign="bottom">6.840213538</td><td align="char" char="hyphen" valign="bottom">3.40E-11</td><td align="char" char="hyphen" valign="bottom">8.93E-11</td></tr><tr><td align="left" valign="bottom"><italic>ZNF598</italic></td><td align="char" char="." valign="bottom">0.62380412</td><td align="char" char="." valign="bottom">4.006663611</td><td align="char" char="." valign="bottom">6.043582081</td><td align="char" char="hyphen" valign="bottom">3.76E-09</td><td align="char" char="hyphen" valign="bottom">8.90E-09</td></tr><tr><td align="left" valign="bottom"><italic>HBS1L</italic></td><td align="char" char="." valign="bottom">0.291107388</td><td align="char" char="." valign="bottom">4.701389722</td><td align="char" char="." valign="bottom">2.72853772</td><td align="char" char="." valign="bottom">0.006672805</td><td align="char" char="." valign="bottom">0.010370549</td></tr><tr><td align="left" valign="bottom"><italic>NEMF</italic></td><td align="char" char="." valign="bottom">0.194631373</td><td align="char" char="." valign="bottom">4.566962778</td><td align="char" char="." valign="bottom">2.575063266</td><td align="char" char="." valign="bottom">0.010419695</td><td align="char" char="." valign="bottom">0.015855894</td></tr><tr><td align="left" valign="bottom"><italic>ANKZF1</italic></td><td align="char" char="." valign="bottom">–0.436070986</td><td align="char" char="." valign="bottom">4.620298333</td><td align="char" char="." valign="bottom">–3.65005718</td><td align="char" char="." valign="bottom">0.000300886</td><td align="char" char="." valign="bottom">0.000525859</td></tr></tbody></table></table-wrap><p>The subsequent experiments were conducted using two GBM cell lines, SF268 (SF in figures) (<xref ref-type="bibr" rid="bib55">Rutka et al., 1987</xref>) and GSC827 (GSC in figures) (<xref ref-type="bibr" rid="bib38">Kim et al., 2013</xref>), and two control cell lines, SVG p12 (SVG in figures) and Normal Human Astrocytes E6/E7/hTERT (NHA in figures) (<xref ref-type="bibr" rid="bib61">Sonoda et al., 2001</xref>). RQC protein expression analysis revealed decreased ANKZF1 and increased ABCE1, ASCC3, and NEMF expression in GSC827 and SF268 cells, consistent with findings in patient-derived GSCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Intriguingly, induction of CAT-tailing on a Flag-tagged β-globin reporter via a nonstop protein translation system demonstrated significantly higher CAT-tailed protein (β-globin-nonstop) production in GBM cells (<xref ref-type="bibr" rid="bib56">Saito et al., 2013</xref>). This process was inhibitable by the CAT-tailing elongation inhibitor anisomycin and NEMF knockdown (sgNEMF), but not cycloheximide treatment, as evidenced by a decreased ratio of CAT-tailed (red) to non-CAT-tailed bands (green) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>Next, to investigate the biological implications of CAT-tailing, artificial CAT-tails were introduced to mitochondrial proteins. Due to the variability in CAT-tailing, prior research simulated this process by adding alanine-threonine (AT) repeat tails to the C-terminus of mitochondrial proteins (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>). According to recent studies, the chosen tail sequence can be stabilized by its high threonine content (<xref ref-type="bibr" rid="bib13">Chang et al., 2024</xref>; <xref ref-type="bibr" rid="bib37">Khan et al., 2024</xref>). ATP5α, a highly abundant mitochondrial protein with roles in cancer, was selected to study the unique functions of CAT-tailed forms (<xref ref-type="bibr" rid="bib49">Morgenstern et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Chang et al., 2023</xref>). siATP5α knockdown first confirmed the upper band signal in GSCs as authentic ATP5α, demonstrated by its disappearance concurrent with the main band’s weakening (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Then, we confirmed that this upper band signal corresponded to changes in CAT-tailing, which could be effectively inhibited by NEMF knockdown and anisomycin treatment (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Due to the indistinct nature of the endogenous msiCAT-tailed ATP5α signal, exogenously expressed Flag-ATP5α was utilized here.</p><p>To investigate the potential new function provided by CAT-tailed proteins, control (SVG and NHA) and GBM (SF268 and GSC827) cell lines overexpressed ATP5α with three (ATP5α-AT3) or twenty (ATP5α-AT20) AT repeats. Consistent with earlier findings, only the long-tailed ATP5α-AT20 exhibited posttranslational modifications and detergent-resistant insoluble aggregates, appearing as slower migrating bands and a high-molecular-weight smear in protein electrophoresis (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Based on comparing exogenously expressed (indicated by red boxes) to endogenous proteins (indicated by green boxes), GBM cell lines (GSC827, SF268) showed increased accumulation of ATP5α-AT20 compared to control cells (SVG, NHA). This accumulation may occur due to increased stability and reduced degradation of long-tailed proteins, a malfunctioning protein quality control system, enhanced cellular tolerance to protein accumulation, or a combination of these factors. Subcellular localization analysis showed that the short AT tail (AT3) did not significantly alter ATP5α’s mitochondrial localization, similar to the tailless protein. However, a significant portion of ATP5α-AT20 was found in the cytoplasm near mitochondria, forming protein aggregates, with the highest proportion in highly malignant GSCs (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C and D</xref>). Notably, poly-glycine-serine tails (short, GS3, and long, GS20) did not induce insoluble protein aggregation or intracellular punctate distribution (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E–G</xref>), highlighting the importance of specific amino acid composition.</p><p>Importantly, in GBM cells, both exogenous tailed proteins and the endogenous ATP5α formed clusters attached to the outer mitochondrial membrane (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). Similar aggregate formation in GBM cells was also observed with other mitochondrial proteins, such as NDUS3 (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A and B</xref>). Furthermore, we examined the mouse GBM models. Akin to in vitro culture, ATP5α in transplanted SB28 glioma formed more punctate signals and did not always colocalize with the mitochondrial marker TOM20 (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C–E</xref>). These findings collectively indicate a disruption of the RQC pathway, leading to the presence of msiCAT-tailed proteins in GBM cells.</p></sec><sec id="s2-2"><title>msiCAT-tailed ATP5α elevates mitochondrial membrane potential (ΔΨm)</title><p>Some cancer cells exhibit altered mitochondrial physiology, maintaining or increasing mitochondrial membrane potential (ΔΨm) despite reduced respiration. This was observed in patient-derived GSCs, which demonstrated higher ΔΨm but lower ATP production than control NSCs (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Similarly, GBM cell lines, GSC827 and SF268, displayed comparable or higher ΔΨm and lower ATP levels relative to the control NHA cell line (<xref ref-type="bibr" rid="bib61">Sonoda et al., 2001</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>). Genetic inhibition of msiCAT-tailing, via NEMF knockdown (sgNEMF) or ANZKF1 overexpression (oeANZKF1) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>), as well as pharmacological inhibition by anisomycin treatment, effectively reduced ΔΨm in GBM cells but not in NHA cells (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Impact of msiCAT-tailed ATP5α proteins on mitochondrial functions in glioblastoma multiforme (GBM) cells.</title><p>(<bold>A</bold>) TMRM staining shows a high mitochondrial membrane potential in patient-derived glioblastoma stem cells (GSCs) (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001). (<bold>B</bold>) ATP measurement shows a low mitochondrial ATP production in patient-derived GSCs (n=3; unpaired Student’s t-test; *<italic>*</italic>, p&lt;0.01; ***, p&lt;0.001). (<bold>C, D</bold>) JC-10 staining reveals a reduced mitochondrial membrane potential in GBM cells, but not in NHA control cells, upon both genetic (<bold>C</bold>) and pharmacological (<bold>D</bold>) inhibition of the mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) pathway (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001; ns, not significant). (<bold>E</bold>) JC-10 staining reveals an increased mitochondrial membrane potential in GBM cells, but not in control cells, upon overexpression of ATP5α-AT3 and ATP5α-AT20 (n=3; unpaired Student’s t-test; ****, p&lt;0.0001; ns, not significant). (<bold>F</bold>) Western blot of FLAG-tagged ATP5α, NEMF, and ANKZF1 in GBM cells and control cells, using ACTIN as the loading control. (<bold>G</bold>) JC-10 staining reveals an increased mitochondrial membrane potential in GBM cells, but not in NHA control cells, upon overexpression of ATP5α-AT3 and ATP5α-AT20 with concurrent genetic inhibition of the endogenous msiCAT-tailing pathway (n=3; unpaired Student’s t-test; *, p&lt;0.05; **, p&lt;0.01). (<bold>H</bold>) Blue Native polyacrylamide gel electrophoresis (BN-PAGE) western blot of ATP5α and Flag shows that ATP5α-AT3 is incorporated into the mitochondrial Complex-V (ATP synthase), while ATP5α-AT20 forms high-molecular-weight protein aggregates in GBM cells. SC: respiratory supercomplex; C-V: Complex-V/ATP synthase. (<bold>I, K</bold>) Oxygen consumption rate (OCR) data indicate a reduction in mitochondrial oxygen consumption in SF268 cells expressing ATP5α-AT3 and ATP5α-AT20. Oligomycin (1.5 µM), FCCP (1.0 µM), and rotenone/antimycin A (R/A, 0.5 µM) were sequentially added. (<bold>J, L</bold>) Statistics of mitochondrial respiration parameters in (<bold>I, K</bold>), including non-mitochondrial respiration, basal respiration, maximum respiration, spare respiration, proton leaks, and ATP production (n=3; unpaired Student’s t-test; *, p&lt;0.05; *<italic>*</italic>, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001; ns, not significant).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig2">Figure 2F and H</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig2">Figure 2F and H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig2">Figure 2A–L</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Aberrant mitochondrial function in glioblastoma multiforme (GBM) cells.</title><p>(<bold>A</bold>) JC-10 staining reveals elevated mitochondrial membrane potentials in GBM cells compared to NHA (control) cells (n=3; unpaired Student’s t-test; ***, p&lt;0.001). (<bold>B</bold>) Analysis with BioTracker ATP‐red dye staining shows reduced mitochondrial ATP production in GBM cells compared to NHA (control) cells, using MitoTracker-Green as the mitochondrial mass indicator for normalization. (<bold>C</bold>) Quantification of (<bold>B</bold>) (n=3; unpaired Student’s t-test; ****, p&lt;0.0001). (<bold>D</bold>) Western blot of NEMF and ANKZF1 in GBM and control cells, confirming the successful overexpression and knockdown of target proteins, using ACTIN as the loading control. (<bold>E</bold>) JC-10 staining reveals no change of mitochondrial membrane potential in GBM cells, upon overexpression of ATP5α-GS3 and ATP5α-GS20 (n=3; unpaired Student’s t-test; ****, p&lt;0.0001; ns, not significant).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, C and E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig2-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Our next investigation of msiCAT tail proteins revealed their impact on mitochondrial function. Expression of Flag-tagged ATP5α-AT3 and ATP5α-AT20 in GBM and control cell lines elevated ΔΨm specifically in GBM cells (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Overexpression of ATP5α-GS3 and ATP5α-GS20 did not exhibit this effect (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). To our surprise, even with suppressed endogenous CAT-tailing through sgNEMF and oeANZKF1 in GSCs, the introduced AT3 and AT20 proteins could still effectively elevate ΔΨm (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). This finding suggests that CAT-tailing of ATP5α may be a significant contributor to the observed mitochondrial phenotype (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Blue Native polyacrylamide gel electrophoresis (BN-PAGE) illustrated distinct effects based on CAT-tail length. ATP5α-AT3 integrated into the mitochondrial respiratory chain complex, whereas ATP5α-AT20 formed high-molecular-weight complexes or remained as monomers (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). In mitochondrial physiological activity assays using the Agilent Cell Mitochondrial Stress Test, the oxygen consumption rate (OCR) was directly measured to assess mitochondrial respiration. Our findings indicate that expressing both ATP5α-AT3 and ATP5α-AT20 negatively impacted mitochondrial oxidative phosphorylation. This impairment leads to a reduction in ATP synthesis, basal respiration, and maximal respiration rates (<xref ref-type="fig" rid="fig2">Figure 2I–L</xref>). These data suggest that both short and long tails on ATP5α proteins influence mitochondrial function, although potentially through different mechanisms. Short CAT-tails may directly act on ATP synthase function and thus affect the respiratory chain complex, while long CAT-tails form protein aggregates, causing mitochondrial proteostasis stress and thus indirectly affecting mitochondrial respiration (<xref ref-type="bibr" rid="bib70">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2024</xref>). This differential impact of CAT-tail length suggests a nuanced regulation of mitochondrial function mediated by ATP5α modifications.</p></sec><sec id="s2-3"><title>msiCAT-tailing influences MPTP dynamics</title><p>Beyond its traditionally recognized role in ATP production, the F<sub>1</sub>F<sub>0</sub> ATP synthase has garnered increasing attention as a potential structural component of the MPTP complex (<xref ref-type="bibr" rid="bib1">Alavian et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Giorgio et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Bonora et al., 2013</xref>). Given the possibility that CAT-tailed proteins like ATP5α might modulate MPTP function, this investigation sought to elucidate the mechanism by which msiCAT-tailing modulates MPTP dynamics (open-close state). Comparative analyses conducted in GBM and control cells revealed that MPTP in GSC827 cells predominantly exists in a closed conformation, indicated by strong Calcein signals. Notably, the treatment of anisomycin, a pharmacological CAT-tailing inhibitor, effectively induced MPTP opening in GSC827 cells, as indicated by decreased Calcein signals (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). This effect was concomitant with the diminished aggregation of endogenous ATP5α (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>). Furthermore, corroborative evidence was obtained through genetic manipulation. Specifically, genetic inhibition of CAT-tailing via NEMF knockdown (sgNEMF) resulted in a similar decrease in Calcein signaling and a reduction in ATP5α accumulation (<xref ref-type="fig" rid="fig3">Figure 3C, D, G, and H</xref>), aligning with the results obtained using anisomycin. In contrast, treatment with cycloheximide, a general translation inhibitor, did not significantly alter Calcein or ATP5α aggregation signals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–D</xref>), suggesting that nonspecific translation inhibition does not impact the mitochondrial MPTP state. The crucial role of CAT-tail modifications on ATP5α in modulating MPTP status was further substantiated by the observation that overexpression of artificially synthesized AT repeat tails (AT3 and AT20) restored Calcein signals despite the inhibition of endogenous CAT-tailing (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) product regulates mitochondrial permeability transition pore (MPTP) status in glioblastoma multiforme (GBM) cells.</title><p>(<bold>A, C</bold>) MPTP activity assay shows reduced MPTP opening in glioblastoma stem cells (GSCs) compared to NHA (control) cells. Pharmacological (A, anisomycin 200 nM) and genetic (sgNEMF) inhibition of CAT-tailing reverse it. (<bold>B, D</bold>) Quantification of (<bold>A, C</bold>) (n=3; unpaired Student’s t-test; ****, p&lt;0.0001; ns, not significant). (<bold>E, G</bold>) Immunofluorescence staining shows that anisomycin treatment (<bold>E</bold>) and sgNEMF (<bold>G</bold>) inhibit endogenous ATP5α protein aggregation in GBM cells, using TOM20 (red) as a mitochondrial marker. (<bold>F, H</bold>) Quantification of (<bold>E, G</bold>) (n=3; chi-squared test; *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001); the total number of cells counted is indicated in the columns. (<bold>I</bold>) The calcium retention capacity (CRC) assay of isolated mitochondria, measured using the Calcium Green-5N dye, reveals a significantly higher CRC in GBM cells compared to control NHA cells. CsA (Cyclosporin A, MPTP inhibitor) serves as a positive control. (<bold>J</bold>) Statistic of (<bold>I</bold>) shows attenuated CRC in mitochondria pre-treated with anisomycin or with sgNEMF (n=10; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001). (<bold>K</bold>) MPTP activity assay shows that ectopic expression of ATP5α-AT3 and ATP5α-AT20 inhibits MPTP opening in GBM cells. (<bold>L</bold>) Quantification of (<bold>K</bold>) (n=3; unpaired Student’s t-test; ****, p&lt;0.0001). (<bold>M</bold>) Blue Native polyacrylamide gel electrophoresis (BN-PAGE) western blot shows that ATP5α-AT3 and ATP5α-AT20 expression alters ANT1/2 protein patterns in GBM cells, resulting in a missing band (circled in yellow dashed line) and formation of high-molecular-weight aggregates. SC: respiratory supercomplex; C-V: Complex V/ATP synthase.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig3">Figure 3M</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig3">Figure 3M</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig3">Figure 3B, D, F, H, I, J, and L</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cycloheximide does not impact mitochondrial functions.</title><p>(<bold>A</bold>) Mitochondrial permeability transition pore (MPTP) activity assay shows that MPTP opening is not affected by the cycloheximide treatment (100 µg/mL) in cells. (<bold>B</bold>) Quantification of (<bold>A</bold>) (n=3; unpaired Student’s t-test; ns, not significant). (<bold>C</bold>) Immunofluorescence staining reveals no inhibition of endogenous ATP5α protein aggregation by cycloheximide (100 µg/mL) treatment in glioblastoma multiforme (GBM) cells, using TOM20 (red) as a mitochondrial marker. (<bold>D</bold>) Quantification of (<bold>C</bold>) (n=3; chi-squared test; ns, not significant); the total number of cells counted is indicated in the columns. (<bold>E</bold>) MPTP activity assay reveals the increased Calcein signal in GBM cells, upon overexpression of ATP5α-AT3 and ATP5α-AT20 with concurrent genetic inhibition of the mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) pathway (n=3; unpaired Student’s t-test; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B, D, and E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>The CAT-tailed ATP5α variant has no interaction with mitochondrial permeability transition pore (MPTP) proteins.</title><p>(<bold>A</bold>) Calcium retention capacity (CRC) assay of isolated mitochondria, measured with Calcium Green-5N dye, upon cycloheximide (100 µg/mL) treatment and CAT-tailing enhancement (oeNEMF and siANKZF1). (<bold>B</bold>) Statistic of (<bold>A</bold>) shows changes in CRC in glioblastoma multiforme (GBM) cells or control cells (n=10; unpaired Student’s t-test; **, p&lt;0.01; ***, p&lt;0.001). (<bold>C</bold>) Co-immunoprecipitation data show no direct interaction between ATP5α and either cyclophilin D (CypD) or ANT1/2 can be found in GBM cells. Red arrowheads indicate target proteins. (<bold>D</bold>) Western blotting of cytosolic and isolated mitochondrial fractions shows ATP5α-AT3 expression reduces CypD levels in GBM cells, using TOM20 as a mitochondrial marker and loading control.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C and D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata2"><label>Figure 3—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig3-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata3"><label>Figure 3—figure supplement 2—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A, B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig3-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig3-figsupp2-v1.tif"/></fig></fig-group><p>The MPTP is recognized to participate in the transient efflux of protons, calcium ions (Ca²<sup>+</sup>), and other signaling molecules from the mitochondrial matrix during brief opening episodes (<xref ref-type="bibr" rid="bib31">Ichas et al., 1997</xref>). To quantitatively evaluate the MPTP open/closed state, the mitochondrial Ca²<sup>+</sup> retention capacity (CRC) assay was employed, which measures the amount of Ca²<sup>+</sup> required to elicit MPTP opening. Our results revealed that GSC827 cells exhibited a greater CRC value than NHA cells. Pre-treatment with anisomycin or knockdown of NEMF (sgNEMF) significantly decreased the CRC in GBM cells, indicating MPTP opening upon the loss of CAT-tailed proteins (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>). Consistent with Calcein staining results (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>), cycloheximide treatment did not substantially alter CRC measurements (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A and B</xref>). Conversely, enhancing CAT-tailing (e.g. via oeNEMF and siANKZF1) led to an increase in CRC (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A and B</xref>), although this effect was less pronounced in GSCs, potentially due to their inherently active CAT-tailing and closed MPTP.</p><p>To further investigate the impact of specific AT repeat tails on MPTP opening, artificial AT repeat tails on ATP5α were introduced into GBM cells. It was found that the short AT tail (AT3) inhibited MPTP opening, while the long AT tail (AT20) displayed a weaker effect (<xref ref-type="fig" rid="fig3">Figure 3K and L</xref>), potentially due to their different integration into ATP synthase (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Complex co-immunoprecipitation (co-IP) assay did not detect direct interactions between ATP5α with AT3 or AT20 tails and MPTP components cyclophilin D (CypD) and adenine nucleotide translocator 2 (ANT2) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). However, CypD expression was reduced upon ectopic expression of ATP5α-AT3 and ATP5α-AT20, suggesting decreased MPTP formation (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>). Intriguingly, BN-PAGE analysis revealed that both ATP5α-AT3 and ATP5α-AT20 altered ANT1/2-containing complexes, with expected bands disappearing (indicated by *) and aggregates forming (at the top), supporting the notion that ATP synthase is integrated into the MPTP supercomplex due to the spatial proximity of the ANT1/2 complex and ATP synthase (<xref ref-type="fig" rid="fig3">Figure 3M</xref>). In conclusion, msiCAT-tailed ATP5α proteins, particularly those with short AT3 tails, are integrated into ATP synthase and have a substantial influence on modulating MPTP status.</p></sec><sec id="s2-4"><title>msiCAT-tailing boosts GBM cell migration and resistance to apoptosis</title><p>The elevated mitochondrial membrane potential (ΔΨm) and constricted MPTP resulting from msiCAT-tailed ATP5α and other mitochondrial proteins may enhance cellular stress resilience. We first investigated how the msiCAT-tailing mechanism affects GBM cells at the cellular level. MTT assays (<xref ref-type="bibr" rid="bib62">Stockert et al., 2018</xref>) revealed that overexpressing short (AT3) and long (AT20) AT repeat tails, fused to ATP5α, significantly improved GBM cell viability, but not that of NHA cells (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). However, short (GS3) and long (GS20) GS repeat tails did not affect GBM cell viability (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). In addition, in vitro transwell migration assays (<xref ref-type="bibr" rid="bib32">Justus et al., 2014</xref>) and wound healing assays (<xref ref-type="bibr" rid="bib26">Grada et al., 2017</xref>) showed that GBM cells overexpressing AT repeat-tailed ATP5α exhibited increased cell invasion and accelerated wound healing, indicating enhanced cell migration (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>). Notably, neither ATP5α alone nor GS repeat-tailed proteins showed comparable changes (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D and E</xref>). Furthermore, overexpressing AT3- and AT20-tailed proteins effectively conferred phenotypes associated with increased GBM cell activity, such as enhanced survival and migration, even with inhibited endogenous CAT-tailing machinery activity (e.g. sgNEMF and oeANKZF1) (<xref ref-type="fig" rid="fig4">Figure 4E–G</xref>). It is worth noting that ANKZF1 knockdown in U87 and U251 cell lines can cause aberrant mitoGFP accumulation, possibly reducing cellular adaptability (<xref ref-type="bibr" rid="bib43">Li et al., 2024</xref>), suggesting varying mitochondrial adaptability to proteostasis stress across cell lines. Supporting this, initial experiments showed that mild expression of ATP5α-AT3 and ATP5α-AT20 did not induce strong mitochondrial proteotoxic responses, as evidenced by the lack of significant upregulation in <italic>LONP1</italic>, <italic>mtHSP70</italic>, and <italic>HSP60</italic> mRNA levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>msiCAT-tailed ATP5α protein promotes glioblastoma multiforme (GBM) progression.</title><p>(<bold>A</bold>) MTT assay indicates increased proliferation caused by ATP5α-AT3 and ATP5α-AT20 expression in GBM cells (n=3; unpaired Student’s t-test; **, p&lt;0.01; ***, p&lt;0.001). (<bold>B</bold>) MTT assay indicates no change in proliferation caused by ATP5α-AT3 and ATP5α-AT20 expression in NHA cells (n=3; unpaired Student’s t-test; ns, not significant). (<bold>C</bold>) Transwell assay reveals enhanced migration induced by ATP5α-AT3 and ATP5α-AT20 expression in GBM (SF) cells but not in control (NHA) cells. (<bold>D</bold>) Quantification of (<bold>C</bold>) shows the number of migrated cells (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ns, not significant). (<bold>E</bold>) MTT assay indicates an increased proliferation in GBM cells, upon overexpression of ATP5α-AT3 and ATP5-AT20 with concurrent genetic inhibition of the endogenous mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) pathway (n=3; unpaired Student’s t-test; *, p&lt;0.05; **, p&lt;0.01). (<bold>F</bold>) Transwell assay reveals enhanced migration upon overexpression of ATP5α-AT3 and ATP5α-AT20 with concurrent genetic inhibition of the endogenous msiCAT-tailing pathway. (<bold>G</bold>) Quantification of (<bold>F</bold>) shows the number of migrated cells (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001). (<bold>H</bold>) TUNEL staining shows that staurosporine (STS, 1 µM)-induced apoptosis is attenuated by ATP5α-AT3 and ATP5α-AT20 expression in GBM cells, using TUNEL-Cy3 as an apoptotic cell indicator and DAPI as a nucleus indicator. (<bold>I</bold>) Quantification of (<bold>H</bold>) shows the percentage of TUNEL-positive cells in the population (n=3; unpaired Student’s t-test; ***, p&lt;0.001), using DMSO as the vehicle control. (<bold>J</bold>) MTT assay indicates an enhanced resistance to temozolomide (TMZ, 150 µM) induced by ATP5α-AT3 and ATP5α-AT20 expression. The TMZ-treated/SF-Ctrl group is used as the control (n=3; unpaired Student’s t-test; ***, p&lt;0.001).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig4">Figure 4A, B, D, E, G, I, and J</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effect of GS repeat tails on glioblastoma multiforme (GBM) proliferation and migration.</title><p>(<bold>A</bold>) MTT assay indicates no significant change in GBM proliferation upon ATP5α-GS3 and ATP5α-GS20 expression (n=3; unpaired Student’s t-test; **, p&lt;0.01; ns, not significant). (<bold>B</bold>) Wound healing assay reveals enhanced GBM migration upon ATP5α-AT3 and ATP5α-AT20 expression. (<bold>C</bold>) Quantification of (<bold>B</bold>) shows an increased healing rate, indicated by scratch wound coverage at both 24 and 48 hr (n=3; unpaired Student’s t-test; **, p&lt;0.01). (<bold>D</bold>) Transwell assay reveals no significant alteration in GBM migration upon ATP5α-GS3 and ATP5α-GS20 expression. (<bold>E</bold>) Quantification of (<bold>D</bold>) shows the number of migrated cells (n=3; unpaired Student’s t-test; ns, not significant). (<bold>F</bold>) qRT-PCR reveals no increase in mRNA levels of mitochondrial unfolded protein response genes, as normalized to <italic>ACTB</italic> as the control (n=4; unpaired Student’s t-test; **, p&lt;0.01; ns, not significant).</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, C, E, and F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Glioblastoma multiforme (GBM) cells exhibit increased resistance to apoptosis.</title><p>(<bold>A</bold>) TUNEL staining shows that GBM cells are more resistant to staurosporine (STS, 1 µM)-induced apoptosis compared to control cells, using TUNEL-Cy3 as an apoptotic cell indicator and DAPI as a nucleus indicator. (<bold>B</bold>) Quantification of A shows the percentage of TUNEL-positive cells in the population (n=3; unpaired Student’s t-test; ***, p&lt;0.0001; ****, p&lt;0.0001), using DMSO as the vehicle control. (<bold>C</bold>) Western blot analysis of PARP shows that GBM cells are more resilient against STS-induced apoptosis at 30, 90, and 180 min posttreatment. Cleaved PARP is used as an apoptosis marker. ACTIN and GAPDH are used as loading controls. Red numbers below each blot represent the ratios of cleaved PARP (c-PARP) to total PARP protein. (<bold>D, F</bold>) Flow cytometry analysis using Annexin V-FITC/Propidium Iodide (PI) staining shows alterations in apoptosis rates in GBM cells upon ATP5α-AT3, ATP5α-AT20, ATP5α-GS3, and ATP5α-GS20 expression. The apoptotic cell population (Annexin V positive, PI negative) is represented in the fourth quadrant (right lower). (<bold>E, G</bold>) Quantification of (<bold>D, F</bold>) shows the percentages of apoptotic cells (n=3; unpaired Student’s t-test; **, p&lt;0.001; ***, p&lt;0.0001).</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata3"><label>Figure 4—figure supplement 2—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B, E, and G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig4-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig4-figsupp2-v1.tif"/></fig></fig-group><p>GBM cells exhibit increased resistance to STS-induced apoptosis, supported by fewer TUNEL-positive cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A and B</xref>) and markedly diminished PARP-1 (poly ADP-ribose polymerase) cleavage (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>), a marker of AIF-mediated apoptosis (<xref ref-type="bibr" rid="bib48">Mashimo et al., 2021</xref>). To investigate the role of CAT-tailed ATP5α proteins in this resistance, we overexpressed proteins with mimetic tails in GBM cells. Overexpression of both short tail (ATP5α-AT3) and long tail (ATP5α-AT20) significantly enhanced resistance to STS-induced apoptosis, as shown by TUNEL staining (<xref ref-type="fig" rid="fig4">Figure 4H and I</xref>) and flow cytometry (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D and E</xref>), indicating a strong link between protein CAT-tailing and tumorigenesis. In contrast, control short (GS3) and long (GS20) GS tails failed to confer such resistance (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2F and G</xref>). Consistent with these findings, overexpression of artificial CAT-tailed ATP5α proteins also increased the resistance of GBM cells to TMZ-induced apoptosis (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Taken together, these results suggest that RQC-induced CAT-tailing on ATP5α protein plays a role in GBM resistance to drug-induced apoptosis.</p></sec><sec id="s2-5"><title>RQC pathway inhibition hinders GBM cell progression</title><p>Prior research indicates the RQC pathway-mediated msiCAT-tailing plays an important role in GBM progression, suggesting it as a potential therapeutic target. To explore this, patient-derived GSC lines were treated with anisomycin, an inhibitor of CAT-tailing. GSC lines displayed higher sensitivity to anisomycin than normal NSCs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Similarly, genetic inhibition of the RQC pathway via NEMF knockdown (sgNEMF) or ANKZF1 overexpression (oeANZKF1) in the SF268 GBM cell line also suppressed GBM growth (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Notably, control NHA cell proliferation was also inhibited by these genetic changes, indicating the broad significance of NEMF and ANKZF1 in cell proliferation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The RQC pathway appears to have a more pronounced effect on GBM cell migration. In in vitro transwell assays, sgNEMF or oeANZKF1 notably decreased GBM cell migration without affecting NHA cells (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Consistently, anisomycin treatment impaired GSC migration, but not NHA cell migration (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Inhibition of mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) impedes glioblastoma multiforme (GBM) progression.</title><p>(<bold>A</bold>) Cell viability assay shows greater sensitivity to anisomycin treatment in patient-derived glioblastoma stem cells (GSCs) than control neural stem cells (NSCs) at 48 hr (n=3; unpaired Student’s t-test; **, p&lt;0.001; ****, p&lt;0.0001; compared to controls at the corresponding dose). (<bold>B</bold>) MTT assay indicates reduced GBM cell proliferation by genetic inhibition of the msiCAT-tailing pathway (n=3; unpaired Student’s t-test; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001, compared to controls at the corresponding time). (<bold>C</bold>) MTT assay indicates reduced NHA cell proliferation by genetic inhibition of the msiCAT-tailing pathway (n=3; unpaired Student’s t-test; **, p&lt;0.01; ****, p&lt;0.0001, compared to controls at the corresponding time). (<bold>D, F</bold>) Transwell assay reveals that both genetic (<bold>D</bold>) and pharmacological (<bold>F</bold>) inhibition of the msiCAT-tailing pathway hampers the migration of GBM cells but not control cells. (<bold>E, G</bold>) Quantification of (<bold>D, F</bold>) showing the number of migrated cells (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001; ns, not significant). (<bold>H, J</bold>) TUNEL staining reveals that both genetic (<bold>H</bold>) and pharmacological (<bold>J</bold>) inhibition of the msiCAT-tailing pathway promote staurosporine (STS)-induced apoptosis in GBM cells, utilizing TUNEL-Cy3 as an apoptotic cell marker and DAPI as a nuclear stain. (<bold>I, K</bold>) Quantification of (<bold>H, J</bold>) showing the percentage of TUNEL-positive cells in the population (n=3; unpaired Student’s t-test; ****, p&lt;0.0001), using DMSO as the vehicle control. (<bold>L</bold>) MTT assay shows that pharmacological inhibition of the msiCAT-tailing pathway decreases the resistance of GBM cells to temozolomide (TMZ, 150 µM) treatment (n=3; unpaired Student’s t-test; * p&lt;0.05; **, p&lt;0.01). (<bold>M</bold>) The neurosphere formation assay shows that reduced spheroid formation, caused by pharmacological inhibition of the msiCAT-tailing pathway, can synergize with TMZ in GBM cells. (<bold>N</bold>) Quantification of (<bold>M</bold>) (n=3; unpaired Student’s t-test; **, p&lt;0.01).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig5">Figure 5A, B, C, E, G, I, K, L, and N</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>No effect of cycloheximide on glioblastoma multiforme (GBM) apoptosis response.</title><p>(<bold>A</bold>) Caspase-3/7 activity assay shows increased apoptosis in GBM cells caused by anisomycin treatment (n=3; unpaired Student’s t-test; ***, p&lt;0.001; ****, p&lt;0.0001; compared to the control group (DMSO) at the corresponding time). (<bold>B, C</bold>) Western blot analysis of PARP in anisomycin-treated and cycloheximide-treated glioblastoma stem cells (GSCs) indicates that pharmacological inhibition of the mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) pathway enhances staurosporine (STS)-induced apoptosis, using ACTIN as a loading control. Red numbers below each blot represent the ratios of cleaved PARP (c-PARP) to total PARP protein. (<bold>D, F</bold>) Flow cytometry analysis using Annexin V-FITC/Propidium Iodide (PI) staining shows alterations in apoptosis rates in GBM cells upon genetic (<bold>D</bold>) and pharmacological (<bold>F</bold>) inhibition of the msiCAT-tailing pathway. The apoptotic cell population (Annexin V positive, PI negative) is represented in the fourth quadrant (right lower). (<bold>E, G</bold>) Quantification of (<bold>D, F</bold>) shows the percentages of apoptotic cells (n=3; unpaired Student’s t-test; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001; ns, not significant).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-99438-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Numerical source data shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, E, and G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99438-fig5-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Further investigation revealed the RQC pathway’s involvement in GBM cell anti-apoptosis, with initial findings pointing to alterations in mitochondrial functions. Prior studies demonstrated that genetic or pharmacological inhibition of the RQC pathway led to a significant decrease in GBM mitochondrial membrane potential (ΔΨm) (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). In GSCs, anisomycin treatment promoted MPTP opening, an effect not seen in NHA cells (<xref ref-type="fig" rid="fig3">Figure 3A–D</xref>). Consequently, GBM cell lines with genetically or pharmacologically inhibited RQC pathways were more susceptible to STS-induced apoptosis, evidenced by elevated executioner caspase 3/7 activity (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), enhanced PARP-1 cleavage (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>), increased TUNEL staining (<xref ref-type="fig" rid="fig5">Figure 5H–K</xref>), and flow cytometry analysis (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D–G</xref>). Notably, general translation inhibition using cycloheximide did not elicit the same apoptotic response (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, D, and E</xref>). Finally, the RQC pathway was also implicated in TMZ-induced cell death. Combining anisomycin with TMZ significantly reduced GBM cell survival (<xref ref-type="fig" rid="fig5">Figure 5L</xref>) and effectively inhibited GSC spheroid growth (<xref ref-type="fig" rid="fig5">Figure 5M and N</xref>). In summary, the RQC pathway plays a critical role in multiple aspects of GBM progression, including proliferation, migration, and survival under apoptotic stress.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The RQC pathway plays a crucial role in managing aberrant proteins produced during translation. This study focused on understanding the consequences of RQC-mediated modification, specifically the addition of msiCAT tails, on mitochondrial proteins such as ATP5α in GBM cells. The findings reveal that GBM cells harboring msiCAT-modified ATP5α exhibit a unique metabolic profile. Despite a reduction in ATP synthesis, these cells maintain their mitochondrial membrane potential (ΔΨm), a key factor for cellular function and survival. Furthermore, they demonstrate enhanced cell survival and motility, characteristics associated with increased tumor invasiveness and metastasis. Notably, the presence of msiCAT-modified ATP5α confers resistance to apoptosis triggered by STS, potentially by modulating the MPTP, a critical regulator of cell death pathways, as illustrated in <xref ref-type="fig" rid="fig6">Figure 6</xref>. These identified traits contribute to an increased aggressiveness of tumors, suggesting that the RQC pathway plays a critical role in cancer cell survival and proliferation. Encouragingly, a recent study also demonstrated the RQC pathway’s involvement in a <italic>Drosophila</italic> model of Notch overexpression-induced brain tumors (<xref ref-type="bibr" rid="bib36">Khaket et al., 2024</xref>). The findings imply modulating the RQC pathway could serve as a promising complementary strategy to existing chemotherapy regimens. By targeting this specific pathway, therapeutic interventions might effectively disrupt the mechanisms that allow cancer cells to evade apoptosis and sustain their energy production under stress, potentially leading to improved treatment outcomes for patients with GBM and other cancers characterized by similar protein modifications.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Impact of msiCAT-tail-modified ATP5α protein on mitochondrial function in glioblastoma multiforme (GBM) cells.</title><p>In healthy cells, ATP5α protein, encoded by the nuclear genome, is imported into the mitochondrial matrix via the TOM/TIM complex through co-translational import and incorporated into ATP synthase (left). Conversely, in GBM cells, the CAT-tailed ATP5α protein can either form aggregates near the mitochondrial outer membrane or be imported into the mitochondria. Within the mitochondrial matrix, proteins with shorter CAT-tails readily integrate into ATP synthase, disrupting its functionality. This dysfunction is characterized by a reduced ATP synthesis rate and proton (H<sup>+</sup>) accumulation, resulting in an elevated mitochondrial membrane potential (ΔΨm). These alterations in ATP synthase ultimately trigger malfunction of the mitochondrial permeability transition pore (MPTP), consequently affecting cell proliferation, migration, and resistance to drug-induced apoptosis (right). Created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/s5e7151">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99438-fig6-v1.tif"/></fig><p>The study of ATP synthase behavior in cancer holds particular importance. During carcinogenesis, ATP synthase frequently relocates to the plasma membrane, where it is referred to as ectopic ATP synthase (eATP synthase). These eATP synthases exhibit catalytic activity, facilitating ATP production in the extracellular space to foster a favorable tumor microenvironment (<xref ref-type="bibr" rid="bib16">Comelli et al., 2016</xref>). Research indicates that eATP synthase assembles initially in mitochondria before being transported to the cell surface via microtubules (<xref ref-type="bibr" rid="bib12">Chang et al., 2023</xref>). However, the specific type of ATP synthase delivered to the plasma membrane remains unclear. Future investigations into the localization of CAT-tailed eATP synthase may offer valuable insights into this process.</p><p>Multiple mitochondrial proteins in cancer cells can likely undergo CAT-tailing in a similar way. These msiCAT-tailed peptides may have varied impacts on mitochondria and cells due to differences in their base proteins. For instance, CAT-tailed COX4 protein might substantially and directly diminish mitochondrial respiratory efficiency. Examining the individual roles of these proteins is important, as the combined effect of their defects may be crucial in understanding observed mitochondrial changes in cancer. A minor caveat here is that the observed effect of the CAT-tails’ presence primarily stems from artificial CAT-tail sequences with a high threonine content, rather than the endogenous CAT-tail protein. It is possible that other sequence components could lead to different effects (<xref ref-type="bibr" rid="bib13">Chang et al., 2024</xref>). A recent study found that ANKZF1 knockdown inhibited GBM progression by causing abnormal protein accumulation in mitochondria (<xref ref-type="bibr" rid="bib43">Li et al., 2024</xref>). This, combined with our data, suggests that balanced ANKZF1 expression and activity are vital for cancer proliferation. Both excess and deficiency may alter cellular adaptability. A minor flaw of that study was the use of a mitochondrial-localized nonstopped GFP protein to induce proteostasis stress and the lack of direct biochemical evidence of CAT-tailed proteins. Our research focuses on endogenous proteins for a detailed analysis of their impact on mitochondria. The rationale is that highly expressed, nonphysiological ectopic proteins might cause general proteostasis failure, masking the specific functions of endogenous proteins. Additionally, the studies used different cell lines. GSC, a patient-derived GBM cell line with greater stemness, might have a distinct mitochondrial status and RQC pathway activity compared to U87 or U251 cell lines. Thus, the conclusions of the two studies are not contradictory but rather complementary, both demonstrating the significance of RQC in tumorigenesis. Our study delves into the mechanistic role of the RQC pathway in GBM, identifying new potential targets for future treatments.</p><p>An in-depth investigation into the quantification of nuclear genome-encoded mitochondrial proteins modified via the msiCAT-tailing mechanism using sophisticated mass spectrometry is a compelling area for future research. Recent work by Lv et al., published in <italic>Cell Reports</italic>, revealed that the cytoplasmic E3 ligase Pirh2 and the mitochondrial protease ClpXP work in conjunction with the established NEMF-ANKZF1 system to break down mitochondrial protein aggregates resulting from ribosome stalling (<xref ref-type="bibr" rid="bib45">Lv et al., 2024</xref>). The increased presence of ClpXP in various cancers could potentially be linked to an increase in msiCAT-tailing products in mitochondria, though further studies are needed to clarify ClpXP’s role in mitochondrial RQC (<xref ref-type="bibr" rid="bib17">Cormio et al., 2021</xref>). Moreover, ClpXP influences the levels of multiple mitochondrial proteins. Our own experiments showed that ATP5α proteins lacking msiCAT-tails were the most challenging to express ectopically. Proteins with shorter tails (AT3) expressed more readily, while those with longer tails (AT20) exhibited the highest expression levels but also tended to form SDS-insoluble aggregates. This regulatory effect could be mediated by ClpXP-dependent degradation or potentially through transcriptional control. PGC-1α, the peroxisome proliferator-activated receptor gamma co-activator, is a key regulator of mitochondrial biogenesis in mammals (<xref ref-type="bibr" rid="bib65">Ventura-Clapier et al., 2008</xref>). By binding to and activating nuclear transcription factors, PGC-1α triggers the transcription of nuclear genome-encoded mitochondrial proteins and the mitochondrial transcription factor Tfam. Tfam, in turn, activates mitochondrial genome transcription and replication (<xref ref-type="bibr" rid="bib69">Wu et al., 1999</xref>). Distinguishing between these regulatory possibilities will necessitate future research, including a meticulous examination of mRNA levels for msiCAT-tailed targets and analysis of PGC-1α and Tfam binding to transcriptional elements.</p><p>MPTP is a complex, supramolecular channel traversing the inner mitochondrial membrane, characterized by its nonselective ion permeability, calcium dependence, and multifaceted functionality. Despite extensive investigations into its functional attributes and regulatory mechanisms, the precise molecular architecture of the MPTP remains elusive (<xref ref-type="bibr" rid="bib21">Endlicher et al., 2023</xref>). Several theoretical models have been posited to elucidate the MPTP’s structural composition. First, the VDAC/ANT/CypD model (<xref ref-type="bibr" rid="bib4">Beutner et al., 1998</xref>) proposed an assembly of voltage-dependent anion channels (VDAC), adenine nucleotide translocators (ANT), and CypD as the structural basis; however, subsequent genetic analyses have introduced substantial controversy regarding the integral role of these proteins within the MPTP complex (<xref ref-type="bibr" rid="bib3">Baines et al., 2007</xref>; <xref ref-type="bibr" rid="bib28">Gutiérrez-Aguilar et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Kokoszka et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Karch et al., 2019</xref>). Second, the ATP synthase model posits that MPTP formation involves dimers or reconstituted c-rings of ATP synthase (<xref ref-type="bibr" rid="bib1">Alavian et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Giorgio et al., 2013</xref>). While this hypothesis presents an intriguing perspective, empirical confirmation of ATP synthase’s role as a definitive structural element of the pore remains inconclusive, with a body of conflicting research surrounding this proposition. Third, the contemporary prevailing hypothesis suggests the MPTP is constituted by a large complex, termed the ATP synthasome, comprising ANT and ATP synthase, with CypD serving a regulatory function over the complex’s dynamic behavior (<xref ref-type="bibr" rid="bib5">Beutner et al., 2017</xref>).</p><p>The MPTP activity is modulated by mitochondrial membrane potential (ΔΨm), which reciprocally influences mitochondrial ion homeostasis and energy metabolism (<xref ref-type="bibr" rid="bib50">Petronilli et al., 1994</xref>; <xref ref-type="bibr" rid="bib8">Boyman et al., 2019</xref>). Our study elucidates a dual function of msiCAT-tailed ATP5α protein in cancer cells: stabilization of a high membrane potential, thereby mitigating MPTP induction, and direct inhibition of MPTP functionality through participation in its assembly. While MPTP’s critical role in cell death is established, the premise that MPTP inhibition enables cancer cell evasion of drug-induced programmed cell death has lacked substantial evidence. This study furnishes empirical support for this hypothesis, demonstrating that GBM cells, notably GSCs, exhibit markedly reduced MPTP activity relative to control cells. This reduced activity is directly correlated with the CAT-tailing modification of the ATP synthase subunit. These observations are concordant with prior research, indicating that genetic mutations or posttranslational modifications in specific ATP synthase subunits can modulate MPTP activity. The findings highlight a novel mechanism through which cancer cells may develop resistance to therapeutic interventions by manipulating mitochondrial function (<xref ref-type="bibr" rid="bib2">Antoniel et al., 2018</xref>; <xref ref-type="bibr" rid="bib10">Carraro et al., 2020</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines and cell culture conditions</title><p>The human astroglia cell line SVG p12 (ATCC, cat. CRL-8621) and the human glioma cell line SF268 were from Dr. Rongze Olivia Lu. Both cell lines were cultured in DMEM (ATCC, cat. #302002) with 10% fetal bovine serum (FBS) (Biowest, cat. S1620-100) and penicillin/streptomycin (Gibco, cat. 15140122). SF268 clones should be maintained in complete DMEM supplemented with 400 µg/mL G418 (Gibco, cat. 10131027). The 0.25% trypsin solution (ATCC, cat. #SM2003C) was used to passage cells. The normal human astrocytes NHA E6/E7/hTERT cell line was from Dr. Russell O Pieper, UCSF Brain Tumor Research Center. Cells are cultured in ABM Basal Medium (Lonza, cat. CC-3187) and AGM SingleQuots Supplements (Lonza, cat. CC-4123). Corning Accutase Cell Detachment Solution (Corning, cat. 25,058CI) was used to passage cells. GSC827, a patient-derived human glioma stem cell line, was from Dr. Chun-Zhang Yang at NIH. The NSC, NSC26, patient-derived GSC33, GSC22, GSC99, GSC105, and GSC107 cell lines used in this study were kindly provided by Dr. John S Kuo at the University of Texas, Austin. Derivation of these lines from patient GBM specimens is described earlier (<xref ref-type="bibr" rid="bib15">Clark et al., 2012</xref>). Detailed characterizations of the GSC lines (not GSC 105 and 107) are available in their previous publication (<xref ref-type="bibr" rid="bib75">Zorniak et al., 2012</xref>). GSC 105 and 107 are not previously published. GSCs were cultured in Neural basal-A Medium (Gibco, cat. #10888022) with 2% B27 (Gibco, cat. #17504044), 1% N2 (Gibco, cat. #17502048), 20 ng/mL of EGF and FGF (Shenandoah Biotechnology Inc, cat. PB-500-017), Antibiotic-Antimycotic (Gibco, cat. #15240062), and L-Glutamine (Gibco, cat. #250300810). Cells could be cultured in both spherical and attached (on Geltrex, Thermo Fisher, cat. A1413202) forms. Corning Accutase Cell Detachment Solution (Corning, cat. 25058CI) was used to passage cells.</p><p>Cells were transfected with X-tremeGENE HP DNA Transfection Reagent (Sigma, cat. 6366244001) following the standard protocol. For single clone selection, SF268 cells were treated with 800 µg/mL G418 for 5 days. The cells were then seeded into a 96-well plate at a density of 1/100 µL. Positive clones were verified by immunofluorescence staining and immunoblotting. Cells were maintained in complete DMEM containing 400 µg/mL G418. GBM cell lines were subjected to a 4 hr pre-treatment at 37°C using either anisomycin (20 nM or 200 nM, Fisher Scientific, cat. AAJ62964MF) or cycloheximide (100 µg/mL, Fisher Scientific, cat. AC357420010) in medium, as detailed in the conducted experiments.</p></sec><sec id="s4-2"><title>Primers, plasmids, and viruses</title><p>Plasmids pcDNA3.1+/C-(K)-DYK-ATP5F1A (pATP5α control), pcDNA3.1+/C-(K)-DYK-ATP5F1A-AT3 (pATP5α-AT3), pcDNA3.1+/C-(K)-DYK-ATP5F1A-AT20 (pATP5α-AT20), pcDNA3.1+/C-(K)-DYK-ATP5F1A-GS3 (pATP5α-GS3), and pcDNA3.1+/C-(K)-ATP5F1A-DYK-GS20 (pATP5α-GS20) were generated by GenScript Inc Plasmids pCMV-5×FLAG-β-globin-control (5FBG-Ctrl) and pCMV-5×FLAG-β-globin-nonstop (5FBG-nonstop) were generated by Dr. Hoshino (Nagoya City University) and Dr. Inada (Tohoku University) (<xref ref-type="bibr" rid="bib56">Saito et al., 2013</xref>). pCMV6-DDK-NEMF (oeNEMF) was from ORIGENE Inc (cat. RC216806L3).</p><p>Viruses (and plasmids used to generate viruses) are pLV[CRISPR]-hCas9:T2A:Neo-U6&gt;Scramble[gRNA#1] (sgControl/sgCtrl), pLV[CRISPR]-hCas9:T2A:Neo-U6&gt;hNEMF[gRNA#1579] (sgNEMF), pLV[Exp]-Bsd-EF1A&gt;ORF_Stuffer (pLV-control), pLV[Exp]-EGFP:T2A:Puro-EF1A&gt;mCherry (pLV-control-2/oeCtrl), pLV[Exp]-Bsd-EF1A&gt;hANKZF1[NM_001042410.2]/HA (oeANKZF1), and pLV[Exp]-mCherry/Neo-EF1A&gt;hANKZF1[NM_001042410.2] (oeANKZF1) were made by VectorBuilder Inc.</p><p>Primers (5’ to 3’) used for RT-PCR are:</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom" rowspan="2"><italic>LONP1</italic><break/>NR_076392.2</td><td align="left" valign="bottom">lonp1_forward: <named-content content-type="sequence">TGCCTTGAACCCTCTCTAC</named-content></td></tr><tr><td align="left" valign="bottom">lonp1_reverse: <named-content content-type="sequence">TCTGCTTGATCTTCTCCTCC</named-content></td></tr><tr><td align="left" valign="top" rowspan="2"><italic>mtHSP70</italic><break/>NM_004134.7</td><td align="left" valign="top">mthsp70_forward: <named-content content-type="sequence">ACTCCTCCATTTATCCGCC</named-content></td></tr><tr><td align="left" valign="top">mthsp70_reverse: <named-content content-type="sequence">ACCTTTGCTTGTTTACCTTCC</named-content></td></tr><tr><td align="left" valign="top" rowspan="2"><italic>HSP60</italic><break/>NM_002156.5</td><td align="left" valign="top">hsp60_forward: <named-content content-type="sequence">ACCTGCTCTTGAAATTGCC</named-content></td></tr><tr><td align="left" valign="top">hsp60_reverse: <named-content content-type="sequence">CAATCCCTCTTCTCCAAACAC</named-content></td></tr><tr><td align="left" valign="top" rowspan="2"><italic>ACTB</italic><break/>NM_001101.5</td><td align="left" valign="top">actb_forward: <named-content content-type="sequence">TGTTTGAGACCTTCAACACC</named-content></td></tr><tr><td align="left" valign="top">actb_reverse: <named-content content-type="sequence">ATGTCACGCACGATTTCC</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-3"><title>Neurosphere formation assay of GSCs</title><p>The GSC spheroids were dissociated using Accutase for 2 min. Cells were resuspended in a single-cell suspension and grown under nonadherent conditions. Cells were seeded in 12-well plates at a density of 0.25×10<sup>6</sup> cells/well and cultured in 3 mL culture medium for 24 hr. 20 nM of anisomycin and 150 µM of TMZ were added to the culture medium, and the cells were treated for 96 hr. Spheroids were imaged under a 10× objective, captured using QCapture, and analyzed with ImageJ. Spheroids larger than 50 µm were counted.</p></sec><sec id="s4-4"><title>Differential gene expression analysis using the public database</title><p>The raw RNA-seq data used for the analysis were obtained from the University of California, Santa Cruz Xenabrowser (cohort: TCGA TARGET GTEx, dataset ID: TcgaTargetGtex_rsem_gene_tpm, <ext-link ext-link-type="uri" xlink:href="https://xena.ucsc.edu/">https://xena.ucsc.edu/</ext-link>). Subsets were then created to include only TCGA glioma (GBM), GTEx Brain Frontal Cortex, and GTEx Cortex samples. Differential expression analysis was conducted using the ‘Limma’ package (R version: 4.3.1). The Benjamini-Hochberg method was used for multiple testing correction to control the false discovery rate. Cutoff of adjusted p-value (adj.P.Val) was set at 0.001; cutoff of the absolute fold change was set at 2 (logFC&gt;1). The code is available without restrictions at <ext-link ext-link-type="uri" xlink:href="https://github.com/yuanna23/GBM_elife">https://github.com/yuanna23/GBM_elife</ext-link>, (copy archived at <xref ref-type="bibr" rid="bib71">Wu, 2026</xref>).</p></sec><sec id="s4-5"><title>Immunostaining</title><p>Cells were cultured on sterile coverslips until 80% confluency. For immunostaining, cells were washed with phosphate-buffered saline (PBS) solution thrice. Then, 4% formaldehyde (Thermo Fisher, cat. BP531-500) was applied to cells for fixation for 30 min at room temperature. After fixation, cells were washed with PBS solution containing 0.25% Triton X-100 (PBSTx) (Thermo Fisher, cat. T9284) thrice and blocked with 5% normal goat serum (Jackson Immuno, cat. 005-000-121) for 1 hr at room temperature. Cells were then incubated with primary antibodies overnight in a humidified chamber at 4°C. The next day, cells were washed by PBSTx thrice and incubated with secondary antibodies for 2 hr at room temperature. After washing, cells were stained with 300 nM DAPI (Thermo Fisher, cat. 57-481-0) for 5 min at room temperature and mounted in Fluoromount-G Anti-Fade solution (Southern Biotech, cat. 0100-35). Images were captured using a Zeiss LSM 800 confocal microscope with a 40× oil objective lens and AiryScan processing. The primary antibodies used in the study were rabbit anti-ATP5a (Cell Signaling, cat. #18023), mouse anti-TOMM20 (1:500, Santa Cruz, cat. sc-17764), rabbit anti-MTCO2 (1:500, Proteintech, cat. 55070-1-AP), and mouse anti-NDUS3 (1:1000, Abcam, cat. ab14711). The secondary antibodies were Alexa Fluor 633-, 594-, 488-conjugated secondary antibodies (1:300, Invitrogen, cat. A21071, A11036, A32732).</p></sec><sec id="s4-6"><title>SDS-PAGE and immunoblotting</title><p>Cells or isolated mitochondria were solubilized in cell lysis buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM EDTA, and 1× protease inhibitor (Bimake, cat. B14002). Protein concentration was measured by using the Bradford assay (BioVision, cat. K813-5000-1). Samples were separated in a 4–12% Tris-Glycine gel (Invitrogen, cat. WXP41220BOX), and proteins were transferred to a PVDF membrane (Millipore, cat. ISEQ00010). The membranes were then blocked with 5% nonfat dry milk (Kroger) for 50 min at room temperature and probed with primary antibodies overnight at 4°C. Membranes were washed with Tris-buffered saline with 0.1% Tween 20 (TBST) solution thrice and then incubated with secondary antibodies for 1 hr at room temperature. Blots were detected with ECL solution (PerkinElmer, cat. NEL122001EA) and imaged by Chemidoc system (Bio-Rad). The intensity of blots was further analyzed by ImageJ software. The primary antibodies used were mouse anti-Actin (1:1000, Santa Cruz, cat. sc-47778), rabbit anti-NEMF (1:1000, Proteintech, cat. 11840-1-AP), mouse anti-ANKZF1 (1:1000, Santa Cruz, cat. sc-398713), mouse anti-ATP5a (Abcam, cat. ab14748), mouse anti-NDUS3 (1:1000, Abcam, cat. ab14711), rabbit anti-COX4 (Abcam, cat. ab209727), mouse anti-Flag (1:1000, Sigma, cat. F1804), rabbit anti-ANT1/2 (1:1000, Proteintech, cat. 17796-1-AP), rabbit anti-CypD (1:1000, Proteintech, cat. 15997-1-AP), rabbit anti-PARP1 (1:1000, Abclonal, cat. A0942), rabbit anti-GAPDH (1:1000, Abclonal, cat. A19056). The secondary antibodies used were goat anti-rabbit IgG (1:5000, Invitrogen, cat. G21234) and goat anti-mouse IgG (1:5000, Invitrogen, cat. PI31430).</p></sec><sec id="s4-7"><title>Mitochondrial isolation, BN-PAGE, and western blotting</title><p>Cells were homogenized using a Dounce homogenizer in ice-cold homogenization buffer containing 210 mM mannitol (Fisher Science, cat. AA3334236), 70 mM sucrose (Fisher Science, cat. AA36508A1), 5 mM HEPES (Fisher Science, cat. 15630106), pH 7.12, 1 mM EGTA (Fisher Science, cat. 28-071-G), and 1× protease inhibitor. The homogenate was centrifuged at 1500×<italic>g</italic> for 5 min. The resultant supernatant was centrifuged at 13,000×<italic>g</italic> for 17 min. The supernatant was collected as the cytosol portion, and the pellet (the mitochondria portion) was washed with homogenization buffer and centrifuged at 13,000×<italic>g</italic> for 10 min. For BN-PAGE, the mitochondrial samples were solubilized in 5% digitonin (Thermo Fisher, cat. BN2006) on ice for 30 min and then centrifuged at 20,000×<italic>g</italic> for 30 min. The supernatant contains solubilized mitochondrial proteins and was mixed with 5% G-250 (GoldBio, cat. C-460-5) and 1× NativePAGE sample buffer (Invitrogen, cat. BN2008) (final G-250 concentration is 25% of the digitonin concentration). Mitochondrial protein concentration was measured by using the Bradford assay. Samples were separated in 3–12% Bis-Tris Native gel (Invitrogen, cat. BN1001BOX) and then transferred to a PVDF membrane. Membranes were fixed with 8% acetic acid (Thermo Fisher, cat. 9526-33), and then blocked and probed with antibodies as described above for western blotting.</p></sec><sec id="s4-8"><title>Mitochondrial membrane potential assays</title><p>Mitochondrial membrane potential of GSCs was measured using Image-iT TMRM (Invitrogen, cat. I34361). Cells were cultured in 96-well black plates at a density of 1×10<sup>5</sup> cells per well overnight in an incubator with 5% CO<sub>2</sub> at 37°C. Cells were incubated with TMRM (100 nM) for 30 min at 37°C. Then, cells were washed with PBS solution three times. Fluorescence changes at excitation/emission of 548/574 nm were monitored with a Cytation 5 plate reader (BioTek). Mitochondrial membrane potential was also measured using JC-10 (AdipoGen, cat. 50-114-6552). Cells were cultured in 96-well black plates at a density of 5×10<sup>4</sup> cells per well overnight in an incubator with 5% CO<sub>2</sub> at 37°C. Cells were incubated with JC-10 (10 µg/mL) for 45 min at 37°C. Then, cells were washed with PBS solution twice. Fluorescence changes at excitation/emission of 535/595 nm for JC-10 aggregates and at 485/535 nm for JC-10 monomers were monitored with a Synergy 2 Reader (BioTek). Mitochondrial membrane potential was quantified as the fluorescence of JC-10 aggregates/monomers (595/535 nm).</p></sec><sec id="s4-9"><title>Seahorse cell mitochondrial stress assays</title><p>The OCR of cells was measured using the Seahorse Cell Mito Stress Test kit following the user guide (Agilent, cat. 103010-100). Briefly, cells were cultured overnight in testing chambers at a density of 8000 cells per well in an incubator with 5% CO<sub>2</sub> at 37°C. Cells were then washed twice with assay medium containing Seahorse XF DMEM medium (Agilent, cat. 103575-100) supplemented with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose. They were subsequently incubated in the assay medium for 1 hr in an incubator without CO<sub>2</sub> at 37°C. Cells were treated with compounds in the order of oligomycin (1.5 µM), carbonyl cyanide-4 (trifluoromethoxy), phenylhydrazone (FCCP, 1.0 µM), and rotenone/antimycin (0.5 µM). The OCR of cells was monitored by using Seahorse XF HS Mini (Agilent).</p></sec><sec id="s4-10"><title>Mitochondrial MPTP assay</title><p>The status of MPTP was measured using Invitrogen Image-IT LIVE Mitochondrial Transition Pore Assay Kit (Invitrogen, cat. I35103). Cells were cultured in 35 mm glass-bottom dishes overnight in an incubator with 5% CO<sub>2</sub> at 37°C. Cells were washed twice with the modified Hank’s Balanced Salt Solution (HBSS, Thermo Fisher, cat. 14025092) containing 10 mM HEPES, 2 mM L-glutamine, and 0.1 mM succinate (Thermo Fisher, cat. 041983.A7) and incubated with the labeling solution (1 µM Calcein, 0.2 µM MitoTracker Red, 1 mM Cobalt Chloride) for 15 min at 37°C. Cells were then washed with HBSS twice and imaged at excitation/emission of 494/517 nm for Calcein and at 579/599 nm for MitoTracker Red by using the Zeiss confocal microscope.</p></sec><sec id="s4-11"><title>Mitochondrial CRC assay</title><p>The mitochondrial CRC was measured on a Cytation 5 reader at excitation/emission of 506/592 nm using the membrane-impermeable fluorescent probe Calcium Green-5N (Invitrogen, cat. C3737). Isolated mitochondria samples (0.75 mg protein/mL) were incubated in 1 mL swelling medium supplemented with 10 mM succinate, 1 μM Calcium Green-5N, inorganic phosphate, and cyclosporine A (Thermo Fisher, cat. AC457970010). One Ca<sup>2+</sup> addition was 1.25 nmol (1 mL volume). Only the MPTP opening in the presence of cyclosporine A was induced by high amounts of added calcium (30 nmol Ca<sup>2+</sup> in the last two additions). The CRC value was calculated as total Ca<sup>2+</sup> accumulated in the mitochondria per unit (1 mg protein).</p></sec><sec id="s4-12"><title>MTT assay</title><p>Cell proliferation was measured by using the MTT assay kit (Roche, cat. 11465007001). Cells were cultured in 96-well plates at a density of 2000 cells per well overnight in an incubator with 5% CO<sub>2</sub> at 37°C. Cells were treated with MTT labeling reagent for 4 hr at 37°C. The solubilization buffer was added to the cells, and then the cells were incubated overnight at 37°C. Absorbance changes of the samples at 550 nm were monitored by using a Synergy 2 Reader (BioTek).</p></sec><sec id="s4-13"><title>Wound healing assay</title><p>Cells were seeded into six-well plates and cultured for 24–48 hr to reach a confluent cell monolayer. Cells were treated with serum-free medium overnight before mechanical scratching (<xref ref-type="bibr" rid="bib26">Grada et al., 2017</xref>). Images of the wounds were taken at 0, 24, and 48 hr. Wound areas were measured by using the wound healing plugin of ImageJ. Wound coverage %=100% x [A<sub>t</sub> –A<sub>t=Dh</sub>]/A<sub>t</sub> (A<sub>t</sub> is the area of the wound measured immediately after scratching t=0 hr, A<sub>t Dh</sub> is the area of the wound measured h hours after the scratch is performed).</p></sec><sec id="s4-14"><title>Cell migration assay</title><p>Cell migration was measured by using Transwell assays (Corning, cat. CLS3422). Cells were cultured in Transwell inserts at a density of 1×10<sup>5</sup> cells per well for 3 hr in an incubator at 37°C with 5% CO<sub>2</sub>. The top inserts were supplemented with DMEM medium only, and the bottom wells were supplemented with DMEM medium with 20% FBS. After incubation, the cells on the apical side of the Transwell insert membrane were removed using a cotton applicator. The cells on the bottom side of the insert were rinsed with PBS twice and fixed in 70% ethanol (Thermo Fisher, cat. R40135) for 15 min at room temperature. After fixation, inserts were placed into an empty well to allow the membrane to dry. Then, the insert was incubated with 0.2% crystal violet (Sigma, cat. V5265) for 5 min at room temperature. The insert was rinsed with water twice, and images were captured by using a microscope with a 20× objective. Cell numbers were quantified using ImageJ.</p></sec><sec id="s4-15"><title>TUNEL staining</title><p>The apoptosis was measured by a TUNEL assay kit (ApexBio, cat. K1134). Cells were cultured on sterile coverslips until 80% confluency and washed with PBS thrice. Then, 4% formaldehyde was applied to cells and fixed at 4°C for 25 min. After fixation, cells were washed with PBS twice and incubated with 20 µM proteinase K (Invitrogen, cat. 25530049) for 5 min at room temperature. Then, cells were rinsed with PBS thrice and incubated in 1× equilibration buffer for 10 min at room temperature. Cells were stained with FITC or Cy3 labeling mix for 1 hr at 37°C in a humidified chamber. Cells were washed with PBS thrice and stained with DAPI for 5 min at room temperature. Cells were mounted in the Fluoromount-G Anti-Fade solution and imaged at 520 nm for FITC or at 570 nm for Cy3 by using the Zeiss confocal microscope.</p></sec><sec id="s4-16"><title>Caspase-3/7 activity assay</title><p>Caspase-3/7 activity was measured by using CellEvent Caspase-3/7 Detection Reagents (Invitrogen, cat. C10432) following the manufacturer’s protocol. Specifically, cells were seeded in a 96-well black plate with a clear bottom at a density of 5×10<sup>4</sup> cells per well and incubated overnight in the incubator with 5% CO<sub>2</sub> at 37°C. Cells were then incubated with 1× staining solution for 30 min at 37°C. Fluorescence changes at excitation/emission of 485/525 nm were monitored with a Synergy 2 Reader (BioTek).</p></sec><sec id="s4-17"><title>Annexin V-FITC/PI apoptosis detection</title><p>Annexin V-FITC/Propidium Iodide (PI) apoptosis assay was performed by using the FITC Annexin V Apoptosis Detection Kit with PI (BioLegend, cat. 640914). Briefly, 1×10<sup>5</sup> cells were collected in 100 μL of staining buffer. Then, cells were incubated with 5 μL of Annexin V-FITC and 2.5 μL of PI for 15 min at room temperature in the dark. Following incubation, 400 μL of binding buffer was added to the stained cells. Flow cytometry analysis of the fluorescence was performed using a Soni SH800 Cell Sorter.</p></sec><sec id="s4-18"><title>Mitochondria ATP measurement via fluorescence imaging of ATP-red</title><p>BioTracker ATP-red dye (Millipore, cat. SCT045) is a fluorogenic indicator for ATP in mitochondria (<xref ref-type="bibr" rid="bib67">Wang et al., 2016</xref>). Cells cultured in monolayer conditions were incubated in medium with 5 μM ATP-red for 15 min in an incubator at 37°C with 5% CO<sub>2</sub>. Mitochondria were also labeled by incubating cells with 100 nM MitoTracker-Green (Invitrogen, cat. M7514) for 15 min to normalize their mass. Before measurement, cells were washed twice with culture medium, and then fresh medium was added. Cells were imaged in a 37°C chamber with 5% CO<sub>2</sub> at excitation/emission of 510/570 nm for ATP-red and at excitation/emission of 490/516 nm for MitoTracker-Green by using the Zeiss confocal microscope. The ATP-red signals could also be measured by a Synergy 2 Reader (BioTek).</p></sec><sec id="s4-19"><title>Co-immunoprecipitation</title><p>Cells were lysed in the buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM EDTA, and 1× protease inhibitor. Soluble samples were incubated with 1.5 µL ATP5α antibody at 4°C with mixing overnight. 25 µL of protein A/G magnetic beads (Pierce, cat. 88802) were added to the co-IP samples and incubated at 4°C with mixing overnight. Samples were washed with washing buffer thrice and then applied to SDS-PAGE analysis.</p></sec><sec id="s4-20"><title>Mice and immunostaining</title><p>Animal studies were approved by the University of California, San Francisco Institutional Animal Care and Use Committee (IACUC, AN195636-01) and were performed following the guidelines of the National Institutes of Health (NIH).</p><p>For orthotopic brain tumor models, 8- to 10-week-old C57BL/6J mice (male and female in equal numbers) were used for i.c. studies. Cell lines (GL261, SB28) were suspended in DMEM for inoculation. Mice were anesthetized with isoflurane, and 30,000 tumor cells were injected orthotopically in 3 μL. Using a stereotactic frame, a burr hole was formed on the skull via a 0.7 mm drill bit 1.5 mm laterally to the right and 1.5 mm rostrally from the bregma, and a noncoring needle (26s gauge; Hamilton) was used to inject the cells at a depth of 3 mm into the brain from the burr hole. The skin incision was sutured. Mice were then monitored daily. Mouse SB28 tumor tissue and wild-type mouse brain tissue were collected at the survival endpoint.</p><p>Frozen tissue sections were thawed at room temperature for 20 min and rinsed with PBS three times. Tissues were then fixed in 4% formaldehyde for 15 min at room temperature. After washing in PBS, tissues were permeabilized with 0.01% Triton X-100+0.1% Tween-20 for 15 min and then blocked by using 5% normal goat serum and M.O.M. blocking reagent (Vector Laboratories, cat. BMK-2202) for 1 hr at room temperature. Tissues were then incubated with primary antibodies overnight in a humidified chamber at 4°C. After washing in PBST, tissues were incubated with secondary antibodies for 1 hr. After washing again in PBST, tissues were stained with 300 nM DAPI for 5 min and mounted in Fluoromount-G Anti-Fade solution. Images were taken using a Zeiss LSM 800 confocal microscope. The primary antibodies used in the study were mouse anti-ATP5a (1:500, Abcam, cat. Ab14748), rat anti-TOMM20 (1:500, Abcam, cat. Ab289670), rabbit anti-NEMF (1:500, Proteintech, cat. 11840-1-AP), mouse anti-ANKZF1 (1:500, Santa Cruz, cat. sc-398713), and chicken anti-GFP (1:500, Abcam, cat. Ab13970). The secondary antibodies were Alexa Fluor 633-, 594-, 488-conjugated secondary antibodies (1:300, Invitrogen, cat. A21071, A11036, A32732).</p></sec><sec id="s4-21"><title>Statistics</title><p>Statistical analyses were performed using GraphPad Prism 9.4. Chi-squared test and unpaired Student’s t-test were used for comparison. p&lt;0.05 was considered significant, except in gene expression analysis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001; ns, not significant. All data were expressed as means ± s.e.m. This study’s replicates, samples, groups, and experiments were biologically independent, except in <xref ref-type="table" rid="table1">Table 1</xref>. The ‘n’ numbers for each assay are indicated in the figure legends.</p></sec><sec id="s4-22"><title>Materials availability</title><p>Plasmids and other reagents generated in this study will be made available to researchers by contacting zhihaowu@smu.edu. The patient-derived materials are proprietary to Prof. John S Kuo, but available on personal requests via standard institution/university agreements.</p></sec><sec id="s4-23"><title>Code availability</title><p>The code used for differential gene expression analysis is available without restrictions at <ext-link ext-link-type="uri" xlink:href="https://github.com/yuanna23/GBM_elife">https://github.com/yuanna23/GBM_elife</ext-link>, (<xref ref-type="bibr" rid="bib71">Wu, 2026</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-99438-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The numerical data used to generate the figures are provided as source data.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><collab>UCSC TOIL RNA-seq recompute</collab></person-group><year iso-8601-date="2016">2016</year><data-title>dataset: gene expression RNAseq - RSEM tpm</data-title><source>UCSC Xena</source><pub-id pub-id-type="accession" xlink:href="https://xenabrowser.net/datapages/?dataset=TcgaTargetGtex_rsem_gene_tpm&amp;host=https%3A%2F%2Ftoil.xenahubs.net&amp;removeHub=http%3A%2F%2F127.0.0.1%3A7222">TcgaTargetGtex_rsem_gene_tpm</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The patient-derived GSC and NSC lines were a gift from Dr. John S Kuo at the University of Texas, Austin. We are also grateful to Dr. Chunzhang Yang at the National Cancer Institute and Dr. Russell O Pieper at the University of California, San Francisco, for the cell lines. We thank Dr. Hoshino at Nagoya City University and Dr. Inada at Tohoku University for providing the plasmids. We also thank the members of the Wu lab at Southern Methodist University and the Lu lab at UCSF for their assistance and discussions. National Institute of General Medical Sciences (R35GM150190), Zhihao Wu. National Institute of Neurological Disorders and Stroke (R01NS126501), Rongze Olivia Lu. Cancer Prevention and Research Institute of Texas (RP210068), Zhihao Wu and Rongze Olivia Lu. Southern Methodist University (Dedman College Dean’s Research Council grant), Zhihao Wu. SPARK-South Carolina Alzheimer’s Disease Research Center (ARDC Pilot Grant), Qing Liu. The funders had no role in the study design, data collection, and interpretation, or in the decision to submit the work for publication.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavian</surname><given-names>KN</given-names></name><name><surname>Beutner</surname><given-names>G</given-names></name><name><surname>Lazrove</surname><given-names>E</given-names></name><name><surname>Sacchetti</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>HA</given-names></name><name><surname>Licznerski</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Nabili</surname><given-names>P</given-names></name><name><surname>Hockensmith</surname><given-names>K</given-names></name><name><surname>Graham</surname><given-names>M</given-names></name><name><surname>Porter</surname><given-names>GA</given-names><suffix>Jr</suffix></name><name><surname>Jonas</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore</article-title><source>PNAS</source><volume>111</volume><fpage>10580</fpage><lpage>10585</lpage><pub-id pub-id-type="doi">10.1073/pnas.1401591111</pub-id><pub-id pub-id-type="pmid">24979777</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniel</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Antonucci</surname><given-names>S</given-names></name><name><surname>Spolaore</surname><given-names>B</given-names></name><name><surname>Fogolari</surname><given-names>F</given-names></name><name><surname>Petronilli</surname><given-names>V</given-names></name><name><surname>Giorgio</surname><given-names>V</given-names></name><name><surname>Carraro</surname><given-names>M</given-names></name><name><surname>Di Lisa</surname><given-names>F</given-names></name><name><surname>Forte</surname><given-names>M</given-names></name><name><surname>Szabó</surname><given-names>I</given-names></name><name><surname>Lippe</surname><given-names>G</given-names></name><name><surname>Bernardi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The unique histidine in OSCP subunit of F-ATP synthase mediates inhibition of the permeability transition pore by acidic pH</article-title><source>EMBO Reports</source><volume>19</volume><fpage>257</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.15252/embr.201744705</pub-id><pub-id pub-id-type="pmid">29217657</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Kaiser</surname><given-names>RA</given-names></name><name><surname>Sheiko</surname><given-names>T</given-names></name><name><surname>Craigen</surname><given-names>WJ</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death</article-title><source>Nature Cell Biology</source><volume>9</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1038/ncb1575</pub-id><pub-id pub-id-type="pmid">17417626</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutner</surname><given-names>G</given-names></name><name><surname>Rück</surname><given-names>A</given-names></name><name><surname>Riede</surname><given-names>B</given-names></name><name><surname>Brdiczka</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore: implication for regulation of permeability transition by the kinases</article-title><source>Biochimica et Biophysica Acta</source><volume>1368</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/s0005-2736(97)00175-2</pub-id><pub-id pub-id-type="pmid">9459579</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beutner</surname><given-names>G</given-names></name><name><surname>Alavian</surname><given-names>KN</given-names></name><name><surname>Jonas</surname><given-names>EA</given-names></name><name><surname>Porter</surname><given-names>GA</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>The mitochondrial permeability transition pore and ATP synthase</chapter-title><person-group person-group-type="editor"><name><surname>Beutner</surname><given-names>G</given-names></name></person-group><source>Handbook of Experimental Pharmacology</source><publisher-name>Springer</publisher-name><fpage>21</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/164_2016_5</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Jones</surname><given-names>T</given-names></name><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Stultz</surname><given-names>B</given-names></name><name><surname>Hursh</surname><given-names>DA</given-names></name><name><surname>Mortin</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title><italic>Drosophila</italic> caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells</article-title><source>Oncogene</source><volume>24</volume><fpage>8229</fpage><lpage>8239</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208962</pub-id><pub-id pub-id-type="pmid">16103875</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>M</given-names></name><name><surname>Bononi</surname><given-names>A</given-names></name><name><surname>De Marchi</surname><given-names>E</given-names></name><name><surname>Giorgi</surname><given-names>C</given-names></name><name><surname>Lebiedzinska</surname><given-names>M</given-names></name><name><surname>Marchi</surname><given-names>S</given-names></name><name><surname>Patergnani</surname><given-names>S</given-names></name><name><surname>Rimessi</surname><given-names>A</given-names></name><name><surname>Suski</surname><given-names>JM</given-names></name><name><surname>Wojtala</surname><given-names>A</given-names></name><name><surname>Wieckowski</surname><given-names>MR</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Pinton</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition</article-title><source>Cell Cycle</source><volume>12</volume><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.4161/cc.23599</pub-id><pub-id pub-id-type="pmid">23343770</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyman</surname><given-names>L</given-names></name><name><surname>Coleman</surname><given-names>AK</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Wescott</surname><given-names>AP</given-names></name><name><surname>Joca</surname><given-names>HC</given-names></name><name><surname>Greiser</surname><given-names>BM</given-names></name><name><surname>Karbowski</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>CW</given-names></name><name><surname>Lederer</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamics of the mitochondrial permeability transition pore: Transient and permanent opening events</article-title><source>Archives of Biochemistry and Biophysics</source><volume>666</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2019.03.016</pub-id><pub-id pub-id-type="pmid">30930285</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandman</surname><given-names>O</given-names></name><name><surname>Stewart-Ornstein</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Larson</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>G-W</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>PS</given-names></name><name><surname>Weibezahn</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JG</given-names></name><name><surname>Rouskin</surname><given-names>S</given-names></name><name><surname>Inada</surname><given-names>T</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress</article-title><source>Cell</source><volume>151</volume><fpage>1042</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.10.044</pub-id><pub-id pub-id-type="pmid">23178123</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Sartori</surname><given-names>G</given-names></name><name><surname>Schiavone</surname><given-names>M</given-names></name><name><surname>Antonucci</surname><given-names>S</given-names></name><name><surname>Kucharczyk</surname><given-names>R</given-names></name><name><surname>di Rago</surname><given-names>JP</given-names></name><name><surname>Franchin</surname><given-names>C</given-names></name><name><surname>Arrigoni</surname><given-names>G</given-names></name><name><surname>Forte</surname><given-names>M</given-names></name><name><surname>Bernardi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The unique cysteine of F-ATP synthase OSCP subunit participates in modulation of the permeability transition pore</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>108095</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108095</pub-id><pub-id pub-id-type="pmid">32877677</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champagne</surname><given-names>J</given-names></name><name><surname>Pataskar</surname><given-names>A</given-names></name><name><surname>Blommaert</surname><given-names>N</given-names></name><name><surname>Nagel</surname><given-names>R</given-names></name><name><surname>Wernaart</surname><given-names>D</given-names></name><name><surname>Ramalho</surname><given-names>S</given-names></name><name><surname>Kenski</surname><given-names>J</given-names></name><name><surname>Bleijerveld</surname><given-names>OB</given-names></name><name><surname>Zaal</surname><given-names>EA</given-names></name><name><surname>Berkers</surname><given-names>CR</given-names></name><name><surname>Altelaar</surname><given-names>M</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name><name><surname>Faller</surname><given-names>WJ</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Oncogene-dependent sloppiness in mRNA translation</article-title><source>Molecular Cell</source><volume>81</volume><fpage>4709</fpage><lpage>4721</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.09.002</pub-id><pub-id pub-id-type="pmid">34562372</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y-W</given-names></name><name><surname>Tony Yang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>M-C</given-names></name><name><surname>Liaw</surname><given-names>Y-G</given-names></name><name><surname>Yin</surname><given-names>C-F</given-names></name><name><surname>Lin-Yan</surname><given-names>X-Q</given-names></name><name><surname>Huang</surname><given-names>T-Y</given-names></name><name><surname>Hou</surname><given-names>J-T</given-names></name><name><surname>Hung</surname><given-names>Y-H</given-names></name><name><surname>Hsu</surname><given-names>C-L</given-names></name><name><surname>Huang</surname><given-names>H-C</given-names></name><name><surname>Juan</surname><given-names>H-F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface</article-title><source>Communications Biology</source><volume>6</volume><elocation-id>427</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-023-04785-3</pub-id><pub-id pub-id-type="pmid">37072500</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WD</given-names></name><name><surname>Yoon</surname><given-names>MJ</given-names></name><name><surname>Yeo</surname><given-names>KH</given-names></name><name><surname>Choe</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Threonine-rich carboxyl-terminal extension drives aggregation of stalled polypeptides</article-title><source>Molecular Cell</source><volume>84</volume><fpage>4334</fpage><lpage>4349</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2024.10.011</pub-id><pub-id pub-id-type="pmid">39488212</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname><given-names>Y-J</given-names></name><name><surname>Park</surname><given-names>S-H</given-names></name><name><surname>Hassemer</surname><given-names>T</given-names></name><name><surname>Körner</surname><given-names>R</given-names></name><name><surname>Vincenz-Donnelly</surname><given-names>L</given-names></name><name><surname>Hayer-Hartl</surname><given-names>M</given-names></name><name><surname>Hartl</surname><given-names>FU</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Failure of RQC machinery causes protein aggregation and proteotoxic stress</article-title><source>Nature</source><volume>531</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/nature16973</pub-id><pub-id pub-id-type="pmid">26934223</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>PA</given-names></name><name><surname>Iida</surname><given-names>M</given-names></name><name><surname>Treisman</surname><given-names>DM</given-names></name><name><surname>Kalluri</surname><given-names>H</given-names></name><name><surname>Ezhilan</surname><given-names>S</given-names></name><name><surname>Zorniak</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Kuo</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition</article-title><source>Neoplasia</source><volume>14</volume><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1596/neo.12432</pub-id><pub-id pub-id-type="pmid">22745588</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comelli</surname><given-names>M</given-names></name><name><surname>Domenis</surname><given-names>R</given-names></name><name><surname>Buso</surname><given-names>A</given-names></name><name><surname>Mavelli</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>F1FO ATP synthase is expressed at the surface of embryonic rat heart-derived H9c2 cells and is affected by cardiac-like differentiation</article-title><source>Journal of Cellular Biochemistry</source><volume>117</volume><fpage>470</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1002/jcb.25295</pub-id><pub-id pub-id-type="pmid">26223201</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormio</surname><given-names>A</given-names></name><name><surname>Sanguedolce</surname><given-names>F</given-names></name><name><surname>Pesce</surname><given-names>V</given-names></name><name><surname>Musicco</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitochondrial caseinolytic protease P: a possible novel prognostic marker and therapeutic target in cancer</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>6228</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22126228</pub-id><pub-id pub-id-type="pmid">34207660</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>S</given-names></name><name><surname>Capone</surname><given-names>F</given-names></name><name><surname>Polo</surname><given-names>A</given-names></name><name><surname>Bagnara</surname><given-names>P</given-names></name><name><surname>Budillon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Valosin-containing protein (VCP)/p97: a prognostic biomarker and therapeutic target in cancer</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>10177</elocation-id><pub-id pub-id-type="doi">10.3390/ijms221810177</pub-id><pub-id pub-id-type="pmid">34576340</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dango</surname><given-names>S</given-names></name><name><surname>Mosammaparast</surname><given-names>N</given-names></name><name><surname>Sowa</surname><given-names>ME</given-names></name><name><surname>Xiong</surname><given-names>L-J</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Rubin</surname><given-names>M</given-names></name><name><surname>Gygi</surname><given-names>S</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation</article-title><source>Molecular Cell</source><volume>44</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.039</pub-id><pub-id pub-id-type="pmid">22055184</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dever</surname><given-names>TE</given-names></name><name><surname>Green</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The elongation, termination, and recycling phases of translation in eukaryotes</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a013706</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a013706</pub-id><pub-id pub-id-type="pmid">22751155</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endlicher</surname><given-names>R</given-names></name><name><surname>Drahota</surname><given-names>Z</given-names></name><name><surname>Štefková</surname><given-names>K</given-names></name><name><surname>Červinková</surname><given-names>Z</given-names></name><name><surname>Kučera</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The Mitochondrial permeability transition pore-current knowledge of its structure, function, and regulation, and optimized methods for evaluating its functional state</article-title><source>Cells</source><volume>12</volume><elocation-id>1273</elocation-id><pub-id pub-id-type="doi">10.3390/cells12091273</pub-id><pub-id pub-id-type="pmid">37174672</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Forrest</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Why cancer cells have a more hyperpolarised mitochondrial membrane potential and emergent prospects for therapy</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/025197</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Mayoh</surname><given-names>C</given-names></name><name><surname>Venkat</surname><given-names>P</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Fletcher</surname><given-names>JI</given-names></name><name><surname>Kamili</surname><given-names>A</given-names></name><name><surname>Gifford</surname><given-names>AJ</given-names></name><name><surname>Kusnadi</surname><given-names>EP</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Haber</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>MD</given-names></name><name><surname>Somers</surname><given-names>K</given-names></name><name><surname>Henderson</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Suppression of ABCE1-Mediated mRNA translation limits N-MYC-driven cancer progression</article-title><source>Cancer Research</source><volume>80</volume><fpage>3706</fpage><lpage>3718</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3914</pub-id><pub-id pub-id-type="pmid">32651259</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrke</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Klinkenberg</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.007</pub-id><pub-id pub-id-type="pmid">25565208</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>V</given-names></name><name><surname>von Stockum</surname><given-names>S</given-names></name><name><surname>Antoniel</surname><given-names>M</given-names></name><name><surname>Fabbro</surname><given-names>A</given-names></name><name><surname>Fogolari</surname><given-names>F</given-names></name><name><surname>Forte</surname><given-names>M</given-names></name><name><surname>Glick</surname><given-names>GD</given-names></name><name><surname>Petronilli</surname><given-names>V</given-names></name><name><surname>Zoratti</surname><given-names>M</given-names></name><name><surname>Szabó</surname><given-names>I</given-names></name><name><surname>Lippe</surname><given-names>G</given-names></name><name><surname>Bernardi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dimers of mitochondrial ATP synthase form the permeability transition pore</article-title><source>PNAS</source><volume>110</volume><fpage>5887</fpage><lpage>5892</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217823110</pub-id><pub-id pub-id-type="pmid">23530243</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grada</surname><given-names>A</given-names></name><name><surname>Otero-Vinas</surname><given-names>M</given-names></name><name><surname>Prieto-Castrillo</surname><given-names>F</given-names></name><name><surname>Obagi</surname><given-names>Z</given-names></name><name><surname>Falanga</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Research techniques made simple: analysis of collective cell migration using the wound healing assay</article-title><source>The Journal of Investigative Dermatology</source><volume>137</volume><fpage>e11</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.11.020</pub-id><pub-id pub-id-type="pmid">28110712</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guièze</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>VM</given-names></name><name><surname>Rosebrock</surname><given-names>D</given-names></name><name><surname>Jourdain</surname><given-names>AA</given-names></name><name><surname>Hernández-Sánchez</surname><given-names>M</given-names></name><name><surname>Martinez Zurita</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ten Hacken</surname><given-names>E</given-names></name><name><surname>Baranowski</surname><given-names>K</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Heo</surname><given-names>JM</given-names></name><name><surname>Cartun</surname><given-names>Z</given-names></name><name><surname>Aygün</surname><given-names>O</given-names></name><name><surname>Iorgulescu</surname><given-names>JB</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Notarangelo</surname><given-names>G</given-names></name><name><surname>Livitz</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Davids</surname><given-names>MS</given-names></name><name><surname>Biran</surname><given-names>A</given-names></name><name><surname>Fernandes</surname><given-names>SM</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Lako</surname><given-names>A</given-names></name><name><surname>Ciantra</surname><given-names>ZB</given-names></name><name><surname>Lawlor</surname><given-names>MA</given-names></name><name><surname>Keskin</surname><given-names>DB</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Letai</surname><given-names>AG</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Ott</surname><given-names>CJ</given-names></name><name><surname>Leshchiner</surname><given-names>I</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Doench</surname><given-names>J</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies</article-title><source>Cancer Cell</source><volume>36</volume><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.08.005</pub-id><pub-id pub-id-type="pmid">31543463</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutiérrez-Aguilar</surname><given-names>M</given-names></name><name><surname>Douglas</surname><given-names>DL</given-names></name><name><surname>Gibson</surname><given-names>AK</given-names></name><name><surname>Domeier</surname><given-names>TL</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name><name><surname>Baines</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>72</volume><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2014.04.008</pub-id><pub-id pub-id-type="pmid">24768964</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>R</given-names></name><name><surname>Nobuta</surname><given-names>R</given-names></name><name><surname>Inada</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of a novel trigger complex that facilitates ribosome-associated quality control in mammalian cells</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>3422</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-60241-w</pub-id><pub-id pub-id-type="pmid">32099016</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heerdt</surname><given-names>BG</given-names></name><name><surname>Houston</surname><given-names>MA</given-names></name><name><surname>Augenlicht</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential</article-title><source>Cancer Research</source><volume>66</volume><fpage>1591</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2717</pub-id><pub-id pub-id-type="pmid">16452217</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichas</surname><given-names>F</given-names></name><name><surname>Jouaville</surname><given-names>LS</given-names></name><name><surname>Mazat</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals</article-title><source>Cell</source><volume>89</volume><fpage>1145</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80301-3</pub-id><pub-id pub-id-type="pmid">9215636</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justus</surname><given-names>CR</given-names></name><name><surname>Leffler</surname><given-names>N</given-names></name><name><surname>Ruiz-Echevarria</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>LV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vitro cell migration and invasion assays</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>51046</elocation-id><pub-id pub-id-type="doi">10.3791/51046</pub-id><pub-id pub-id-type="pmid">24962652</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juszkiewicz</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Initiation of quality control during Poly(A) translation requires site-specific ribosome ubiquitination</article-title><source>Molecular Cell</source><volume>65</volume><fpage>743</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.11.039</pub-id><pub-id pub-id-type="pmid">28065601</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juszkiewicz</surname><given-names>S</given-names></name><name><surname>Speldewinde</surname><given-names>SH</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Svejstrup</surname><given-names>JQ</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ASC-1 complex disassembles collided ribosomes</article-title><source>Molecular Cell</source><volume>79</volume><fpage>603</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.006</pub-id><pub-id pub-id-type="pmid">32579943</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karch</surname><given-names>J</given-names></name><name><surname>Bround</surname><given-names>MJ</given-names></name><name><surname>Khalil</surname><given-names>H</given-names></name><name><surname>Sargent</surname><given-names>MA</given-names></name><name><surname>Latchman</surname><given-names>N</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name><name><surname>Peixoto</surname><given-names>PM</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibition of mitochondrial permeability transition by deletion of the ANT family and CypD</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaaw4597</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aaw4597</pub-id><pub-id pub-id-type="pmid">31489369</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaket</surname><given-names>TP</given-names></name><name><surname>Rimal</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bhurtel</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Ribosome stalling during <italic>c-myc</italic> translation presents actionable cancer cell vulnerability</article-title><source>PNAS Nexus</source><volume>3</volume><elocation-id>pgae321</elocation-id><pub-id pub-id-type="doi">10.1093/pnasnexus/pgae321</pub-id><pub-id pub-id-type="pmid">39161732</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>D</given-names></name><name><surname>Vinayak</surname><given-names>AA</given-names></name><name><surname>Sitron</surname><given-names>CS</given-names></name><name><surname>Brandman</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mechanochemical forces regulate the composition and fate of stalled nascent chains</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.08.02.606406</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Woo</surname><given-names>D-H</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>N</given-names></name><name><surname>Oh</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Rheey</surname><given-names>J</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Joo</surname><given-names>KM</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name><name><surname>Nam</surname><given-names>D-H</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells</article-title><source>Cancer Cell</source><volume>23</volume><fpage>839</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.04.008</pub-id><pub-id pub-id-type="pmid">23684459</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KQ</given-names></name><name><surname>Zaher</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Canary in a coal mine: collided ribosomes as sensors of cellular conditions</article-title><source>Trends in Biochemical Sciences</source><volume>47</volume><fpage>82</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2021.09.001</pub-id><pub-id pub-id-type="pmid">34607755</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokoszka</surname><given-names>JE</given-names></name><name><surname>Waymire</surname><given-names>KG</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Sligh</surname><given-names>JE</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>DP</given-names></name><name><surname>MacGregor</surname><given-names>GR</given-names></name><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore</article-title><source>Nature</source><volume>427</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nature02229</pub-id><pub-id pub-id-type="pmid">14749836</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostova</surname><given-names>KK</given-names></name><name><surname>Hickey</surname><given-names>KL</given-names></name><name><surname>Osuna</surname><given-names>BA</given-names></name><name><surname>Hussmann</surname><given-names>JA</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>DE</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CAT-tailing as a fail-safe mechanism for efficient degradation of stalled nascent polypeptides</article-title><source>Science</source><volume>357</volume><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1126/science.aam7787</pub-id><pub-id pub-id-type="pmid">28751611</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Tantray</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Glynn</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Quality-control mechanisms targeting translationally stalled and C-terminally extended poly(GR) associated with ALS/FTD</article-title><source>PNAS</source><volume>117</volume><fpage>25104</fpage><lpage>25115</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005506117</pub-id><pub-id pub-id-type="pmid">32958650</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>ANKZF1 knockdown inhibits glioblastoma progression by promoting intramitochondrial protein aggregation through mitoRQC</article-title><source>Cancer Letters</source><volume>591</volume><elocation-id>216895</elocation-id><pub-id pub-id-type="doi">10.1016/j.canlet.2024.216895</pub-id><pub-id pub-id-type="pmid">38670305</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberti</surname><given-names>MV</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The warburg effect: how does it benefit cancer cells?</article-title><source>Trends in Biochemical Sciences</source><volume>41</volume><elocation-id>287</elocation-id><pub-id pub-id-type="doi">10.1016/j.tibs.2016.01.004</pub-id><pub-id pub-id-type="pmid">29482833</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Mo</surname><given-names>J</given-names></name><name><surname>Qing</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Mei</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>NEMF-mediated Listerin-independent mitochondrial translational surveillance by E3 ligase Pirh2 and mitochondrial protease ClpXP</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>113860</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.113860</pub-id><pub-id pub-id-type="pmid">38412092</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lytvynenko</surname><given-names>I</given-names></name><name><surname>Paternoga</surname><given-names>H</given-names></name><name><surname>Thrun</surname><given-names>A</given-names></name><name><surname>Balke</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>TA</given-names></name><name><surname>Chiang</surname><given-names>CH</given-names></name><name><surname>Nagler</surname><given-names>K</given-names></name><name><surname>Tsaprailis</surname><given-names>G</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Bischofs</surname><given-names>I</given-names></name><name><surname>Maupin-Furlow</surname><given-names>JA</given-names></name><name><surname>Spahn</surname><given-names>CMT</given-names></name><name><surname>Joazeiro</surname><given-names>CAP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Alanine tails signal proteolysis in bacterial ribosome-associated quality control</article-title><source>Cell</source><volume>178</volume><fpage>76</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.002</pub-id><pub-id pub-id-type="pmid">31155236</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Maria</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Biochemistry, Electron Transport Chain</source><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashimo</surname><given-names>M</given-names></name><name><surname>Onishi</surname><given-names>M</given-names></name><name><surname>Uno</surname><given-names>A</given-names></name><name><surname>Tanimichi</surname><given-names>A</given-names></name><name><surname>Nobeyama</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Negi</surname><given-names>S</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Kato</surname><given-names>J</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><name><surname>Sanada</surname><given-names>N</given-names></name><name><surname>Kizu</surname><given-names>R</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100046</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.RA120.014479</pub-id><pub-id pub-id-type="pmid">33168626</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgenstern</surname><given-names>M</given-names></name><name><surname>Stiller</surname><given-names>SB</given-names></name><name><surname>Lübbert</surname><given-names>P</given-names></name><name><surname>Peikert</surname><given-names>CD</given-names></name><name><surname>Dannenmaier</surname><given-names>S</given-names></name><name><surname>Drepper</surname><given-names>F</given-names></name><name><surname>Weill</surname><given-names>U</given-names></name><name><surname>Höß</surname><given-names>P</given-names></name><name><surname>Feuerstein</surname><given-names>R</given-names></name><name><surname>Gebert</surname><given-names>M</given-names></name><name><surname>Bohnert</surname><given-names>M</given-names></name><name><surname>van der Laan</surname><given-names>M</given-names></name><name><surname>Schuldiner</surname><given-names>M</given-names></name><name><surname>Schütze</surname><given-names>C</given-names></name><name><surname>Oeljeklaus</surname><given-names>S</given-names></name><name><surname>Pfanner</surname><given-names>N</given-names></name><name><surname>Wiedemann</surname><given-names>N</given-names></name><name><surname>Warscheid</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Definition of a high-confidence mitochondrial proteome at quantitative scale</article-title><source>Cell Reports</source><volume>19</volume><fpage>2836</fpage><lpage>2852</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.014</pub-id><pub-id pub-id-type="pmid">28658629</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petronilli</surname><given-names>V</given-names></name><name><surname>Nicolli</surname><given-names>A</given-names></name><name><surname>Costantini</surname><given-names>P</given-names></name><name><surname>Colonna</surname><given-names>R</given-names></name><name><surname>Bernardi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Regulation of the permeability transition pore, a voltage-dependent mitochondrial channel inhibited by cyclosporin A</article-title><source>Biochimica et Biophysica Acta</source><volume>1187</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/0005-2728(94)90122-8</pub-id><pub-id pub-id-type="pmid">7521212</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamoorthy</surname><given-names>MD</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Ayyavu</surname><given-names>M</given-names></name><name><surname>Dhiraviam</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reserpine induces apoptosis and cell cycle arrest in hormone independent prostate cancer cells through mitochondrial membrane potential failure</article-title><source>Anti-Cancer Agents in Medicinal Chemistry</source><volume>18</volume><fpage>1313</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.2174/1871520618666180209152215</pub-id><pub-id pub-id-type="pmid">29424320</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimal</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Vartak</surname><given-names>R</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Tantray</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huh</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Glabe</surname><given-names>C</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimer’s disease</article-title><source>Acta Neuropathologica Communications</source><volume>9</volume><elocation-id>169</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-021-01268-6</pub-id><pub-id pub-id-type="pmid">34663454</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robichaud</surname><given-names>N</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translational control in cancer</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a032896</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a032896</pub-id><pub-id pub-id-type="pmid">29959193</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Mülleder</surname><given-names>M</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Mata</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ribosome profiling reveals ribosome stalling on tryptophan codons and ribosome queuing upon oxidative stress in fission yeast</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>383</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1180</pub-id><pub-id pub-id-type="pmid">33313903</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutka</surname><given-names>JT</given-names></name><name><surname>Giblin</surname><given-names>JR</given-names></name><name><surname>Dougherty</surname><given-names>DY</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><name><surname>McCulloch</surname><given-names>JR</given-names></name><name><surname>Bell</surname><given-names>CW</given-names></name><name><surname>Stern</surname><given-names>RS</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name><name><surname>Rosenblum</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Establishment and characterization of five cell lines derived from human malignant gliomas</article-title><source>Acta Neuropathologica</source><volume>75</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1007/BF00686798</pub-id><pub-id pub-id-type="pmid">2829496</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Hosoda</surname><given-names>N</given-names></name><name><surname>Hoshino</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Hbs1-Dom34 protein complex functions in non-stop mRNA decay in mammalian cells</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>17832</fpage><lpage>17843</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.448977</pub-id><pub-id pub-id-type="pmid">23667253</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reconstitution of a minimal ribosome-associated ubiquitination pathway with purified factors</article-title><source>Molecular Cell</source><volume>55</volume><fpage>880</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.07.006</pub-id><pub-id pub-id-type="pmid">25132172</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>PS</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Parsawar</surname><given-names>K</given-names></name><name><surname>Larson</surname><given-names>MH</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Lambowitz</surname><given-names>AM</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Brandman</surname><given-names>O</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protein synthesis: Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains</article-title><source>Science</source><volume>347</volume><fpage>75</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1126/science.1259724</pub-id><pub-id pub-id-type="pmid">25554787</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>SK</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Iyer</surname><given-names>SV</given-names></name><name><surname>Wang</surname><given-names>H-Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Tabar</surname><given-names>V</given-names></name><name><surname>Gutin</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>De Brabander</surname><given-names>JK</given-names></name><name><surname>Parada</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</article-title><source>Nature</source><volume>567</volume><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0993-x</pub-id><pub-id pub-id-type="pmid">30842654</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitron</surname><given-names>CS</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Giafaglione</surname><given-names>JM</given-names></name><name><surname>Brandman</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aggregation of CAT tails blocks their degradation and causes proteotoxicity in <italic>S. cerevisiae</italic></article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0227841</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0227841</pub-id><pub-id pub-id-type="pmid">31945107</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Hirose</surname><given-names>Y</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name><name><surname>Pieper</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma</article-title><source>Cancer Research</source><volume>61</volume><fpage>4956</fpage><lpage>4960</lpage><pub-id pub-id-type="pmid">11431323</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockert</surname><given-names>JC</given-names></name><name><surname>Horobin</surname><given-names>RW</given-names></name><name><surname>Colombo</surname><given-names>LL</given-names></name><name><surname>Blázquez-Castro</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tetrazolium salts and formazan products in cell biology: viability assessment, fluorescence imaging, and labeling perspectives</article-title><source>Acta Histochemica</source><volume>120</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.acthis.2018.02.005</pub-id><pub-id pub-id-type="pmid">29496266</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaramoorthy</surname><given-names>E</given-names></name><name><surname>Leonard</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Fulzele</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ZNF598 and RACK1 regulate mammalian ribosome-associated quality control function by mediating regulatory 40S ribosomal ubiquitylation</article-title><source>Molecular Cell</source><volume>65</volume><fpage>751</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.12.026</pub-id><pub-id pub-id-type="pmid">28132843</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varn</surname><given-names>FS</given-names></name><name><surname>Johnson</surname><given-names>KC</given-names></name><name><surname>Martinek</surname><given-names>J</given-names></name><name><surname>Huse</surname><given-names>JT</given-names></name><name><surname>Nasrallah</surname><given-names>MP</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>LAD</given-names></name><name><surname>Malta</surname><given-names>TM</given-names></name><name><surname>Wade</surname><given-names>TE</given-names></name><name><surname>Sabedot</surname><given-names>TS</given-names></name><name><surname>Brat</surname><given-names>D</given-names></name><name><surname>Gould</surname><given-names>PV</given-names></name><name><surname>Wöehrer</surname><given-names>A</given-names></name><name><surname>Aldape</surname><given-names>K</given-names></name><name><surname>Ismail</surname><given-names>A</given-names></name><name><surname>Sivajothi</surname><given-names>SK</given-names></name><name><surname>Barthel</surname><given-names>FP</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kocakavuk</surname><given-names>E</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Datta</surname><given-names>I</given-names></name><name><surname>Moon</surname><given-names>H-E</given-names></name><name><surname>Pollock</surname><given-names>S</given-names></name><name><surname>Goldfarb</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>G-H</given-names></name><name><surname>Garofano</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>KJ</given-names></name><name><surname>Nehar-Belaid</surname><given-names>D</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name><name><surname>Bakas</surname><given-names>S</given-names></name><name><surname>Byrne</surname><given-names>AT</given-names></name><name><surname>D’Angelo</surname><given-names>F</given-names></name><name><surname>Gan</surname><given-names>HK</given-names></name><name><surname>Khasraw</surname><given-names>M</given-names></name><name><surname>Migliozzi</surname><given-names>S</given-names></name><name><surname>Ormond</surname><given-names>DR</given-names></name><name><surname>Paek</surname><given-names>SH</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name><name><surname>Walenkamp</surname><given-names>AME</given-names></name><name><surname>Watts</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>T</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Stead</surname><given-names>LF</given-names></name><name><surname>Poisson</surname><given-names>LM</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Iavarone</surname><given-names>A</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><collab>GLASS Consortium</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Glioma progression is shaped by genetic evolution and microenvironment interactions</article-title><source>Cell</source><volume>185</volume><fpage>2184</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.04.038</pub-id><pub-id pub-id-type="pmid">35649412</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura-Clapier</surname><given-names>R</given-names></name><name><surname>Garnier</surname><given-names>A</given-names></name><name><surname>Veksler</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha</article-title><source>Cardiovascular Research</source><volume>79</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvn098</pub-id><pub-id pub-id-type="pmid">18430751</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Reichermeier</surname><given-names>KM</given-names></name><name><surname>Burroughs</surname><given-names>AM</given-names></name><name><surname>Oania</surname><given-names>RS</given-names></name><name><surname>Reitsma</surname><given-names>JM</given-names></name><name><surname>Aravind</surname><given-names>L</given-names></name><name><surname>Deshaies</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Vms1 and ANKZF1 peptidyl-tRNA hydrolases release nascent chains from stalled ribosomes</article-title><source>Nature</source><volume>557</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0022-5</pub-id><pub-id pub-id-type="pmid">29632312</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Er</surname><given-names>JC</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Agrawalla</surname><given-names>BK</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A multisite‐binding switchable fluorescent probe for monitoring mitochondrial atp level fluctuation in live cells</article-title><source>Angewandte Chemie International Edition</source><volume>55</volume><fpage>1773</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1002/anie.201510003</pub-id><pub-id pub-id-type="pmid">26676712</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-wide transcriptome and translatome analyses reveal the role of protein extension and domestication in liver cancer oncogenesis</article-title><source>Molecular Genetics and Genomics</source><volume>296</volume><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1007/s00438-021-01766-1</pub-id><pub-id pub-id-type="pmid">33575838</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Adelmant</surname><given-names>G</given-names></name><name><surname>Mootha</surname><given-names>V</given-names></name><name><surname>Troy</surname><given-names>A</given-names></name><name><surname>Cinti</surname><given-names>S</given-names></name><name><surname>Lowell</surname><given-names>B</given-names></name><name><surname>Scarpulla</surname><given-names>RC</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1</article-title><source>Cell</source><volume>98</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80611-X</pub-id><pub-id pub-id-type="pmid">10412986</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Tantray</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>Z</given-names></name><name><surname>Sitron</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Gispert</surname><given-names>S</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Brandman</surname><given-names>O</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MISTERMINATE mechanistically links mitochondrial dysfunction with proteostasis failure</article-title><source>Molecular Cell</source><volume>75</volume><fpage>835</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.06.031</pub-id><pub-id pub-id-type="pmid">31378462</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2026">2026</year><data-title>GBM_elife</data-title><version designator="swh:1:rev:da2f427a81e5e0543dcd9483c9ac5a517625030e">swh:1:rev:da2f427a81e5e0543dcd9483c9ac5a517625030e</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:97ec72ff1f003c606b0b5874a2ab8e7565645480;origin=https://github.com/yuanna23/GBM_elife;visit=swh:1:snp:e6d088f350775fa846c2564485a5d3ac3469d0ae;anchor=swh:1:rev:da2f427a81e5e0543dcd9483c9ac5a517625030e">https://archive.softwareheritage.org/swh:1:dir:97ec72ff1f003c606b0b5874a2ab8e7565645480;origin=https://github.com/yuanna23/GBM_elife;visit=swh:1:snp:e6d088f350775fa846c2564485a5d3ac3469d0ae;anchor=swh:1:rev:da2f427a81e5e0543dcd9483c9ac5a517625030e</ext-link></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Zinc finger protein 598 inhibits cell survival by promoting UV-induced apoptosis</article-title><source>Oncotarget</source><volume>9</volume><fpage>5906</fpage><lpage>5918</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23643</pub-id><pub-id pub-id-type="pmid">29464043</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonashiro</surname><given-names>R</given-names></name><name><surname>Tahara</surname><given-names>EB</given-names></name><name><surname>Bengtson</surname><given-names>MH</given-names></name><name><surname>Khokhrina</surname><given-names>M</given-names></name><name><surname>Lorenz</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Kigoshi-Tansho</surname><given-names>Y</given-names></name><name><surname>Savas</surname><given-names>JN</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Kay</surname><given-names>SA</given-names></name><name><surname>Craig</surname><given-names>EA</given-names></name><name><surname>Mogk</surname><given-names>A</given-names></name><name><surname>Bukau</surname><given-names>B</given-names></name><name><surname>Joazeiro</surname><given-names>CAP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Rqc2/Tae2 subunit of the ribosome-associated quality control (RQC) complex marks ribosome-stalled nascent polypeptide chains for aggregation</article-title><source>eLife</source><volume>5</volume><elocation-id>e11794</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11794</pub-id><pub-id pub-id-type="pmid">26943317</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shang</surname><given-names>YN</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>CW</given-names></name><name><surname>Mo</surname><given-names>XM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>High <italic>ANKZF1</italic> expression is associated with poor overall survival and recurrence-free survival in colon cancer</article-title><source>Future Oncology</source><volume>15</volume><fpage>2093</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.2217/fon-2018-0920</pub-id><pub-id pub-id-type="pmid">31257922</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorniak</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>PA</given-names></name><name><surname>Leeper</surname><given-names>HE</given-names></name><name><surname>Tipping</surname><given-names>MD</given-names></name><name><surname>Francis</surname><given-names>DM</given-names></name><name><surname>Kozak</surname><given-names>KR</given-names></name><name><surname>Salamat</surname><given-names>MS</given-names></name><name><surname>Kuo</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential expression of 2’,3’-cyclic-nucleotide 3’-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival</article-title><source>Clinical Cancer Research</source><volume>18</volume><fpage>3628</fpage><lpage>3636</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0339</pub-id><pub-id pub-id-type="pmid">22589395</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorova</surname><given-names>LD</given-names></name><name><surname>Popkov</surname><given-names>VA</given-names></name><name><surname>Plotnikov</surname><given-names>EY</given-names></name><name><surname>Silachev</surname><given-names>DN</given-names></name><name><surname>Pevzner</surname><given-names>IB</given-names></name><name><surname>Jankauskas</surname><given-names>SS</given-names></name><name><surname>Babenko</surname><given-names>VA</given-names></name><name><surname>Zorov</surname><given-names>SD</given-names></name><name><surname>Balakireva</surname><given-names>AV</given-names></name><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name><name><surname>Zorov</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial membrane potential</article-title><source>Analytical Biochemistry</source><volume>552</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2017.07.009</pub-id><pub-id pub-id-type="pmid">28711444</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Strain, strain background (mice)</td><td align="left" valign="top"><italic>C57BL/6</italic>J mice</td><td align="left" valign="top">Dr. Rongze Olivia Lu</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="top">SVG p12</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CRL-8621">CRL-8621</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">SF268</td><td align="left" valign="top">Dr. Rongze Olivia Lu</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_1689">CVCL_1689</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GL261</td><td align="left" valign="top">Dr. Rongze Olivia Lu</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_Y003">CVCL_Y003</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">SB28</td><td align="left" valign="top">Dr. Rongze Olivia Lu</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_A5ED">CVCL_A5ED</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC827</td><td align="left" valign="top">Dr. Chun-Zhang Yang</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">NSC</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Human-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">NSC26</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Human-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC33</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC22</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC99</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC105</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">GSC107</td><td align="left" valign="top">Dr. John S Kuo</td><td align="left" valign="top"/><td align="left" valign="top">Patient-derived</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">NHA</td><td align="left" valign="top">Dr. Russell O Pieper</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_E3G5">CVCL_E3G5</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[CRISPR]-hCas9:T2A:Neo-U6&gt;Scramble [gRNA#1]</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB240227-1635qjy</td><td align="left" valign="top">Lentiviral construct to express control sgRNA.</td></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[CRISPR]-hCas9:T2A:Neo-U6&gt;hNEMF [gRNA#1579]</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB900124-2190daq</td><td align="left" valign="top">Lentiviral construct to express human NEMF sgRNA</td></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[Exp]-Bsd-EF1A&gt;ORF_Stuffer</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB900145-3633yjp</td><td align="left" valign="top">The control lentiviral construct to express target gene</td></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[Exp]-EGFP:T2A:Puro-EF1A&gt;mCherry</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB010000-9298rtf</td><td align="left" valign="top">The control lentiviral construct to express target gene</td></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[Exp]-Bsd-EF1A&gt;hANKZF1 [NM_001042410.2]/HA</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB240227-1626epe</td><td align="left" valign="top">Lentiviral construct to express human ANKZF1 gene</td></tr><tr><td align="left" valign="top">Transfected construct (human)</td><td align="left" valign="top">pLV[Exp]-mCherry/Neo-EF1A&gt;hANKZF1 [NM_001042410.2]</td><td align="left" valign="top">Made by VectorBuilder</td><td align="left" valign="top">Cat#: VB900124-2193gcv</td><td align="left" valign="top">Lentiviral construct to express human ANKZF1 gene</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-COX4 (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#: ab209727,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3717302">AB_3717302</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-β-Actin [C4] (Mouse monoclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">Cat#: sc-47778,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_626632">AB_626632</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Flag (Mouse monoclonal)</td><td align="left" valign="top">Millipore Sigma</td><td align="left" valign="top">Cat#: F1804,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_262044">AB_262044</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ANT1/2 (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#: 17796-1-AP,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2190358">AB_2190358</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-CypD (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#: 15997-1-AP,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2190199">AB_2190199</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ATP5a (Rabbit polyclonal)</td><td align="left" valign="top">Cell Signaling Technology</td><td align="left" valign="top">Cat#: 18023,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2687556">AB_2687556</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-PARP1 (Rabbit polyclonal)</td><td align="left" valign="top">Abclonal</td><td align="left" valign="top">Cat#: A0942,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2757470">AB_2757470</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-GAPDH (Rabbit polyclonal)</td><td align="left" valign="top">Abclonal</td><td align="left" valign="top">Cat#: A19056,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2862549">AB_2862549</ext-link></td><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-TOMM20 (Mouse monoclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">Cat#: sc-17764,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_628381">AB_628381</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-MTCO2 (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#: 55070-1-AP,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10859832">AB_10859832</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-NDUS3 (Mouse monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#: ab14711,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_301429">AB_301429</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-NEMF (Rabbit polyclonal)</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#: 11840-1-AP,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2183413">AB_2183413</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ANKZF1 (Mouse monoclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">Cat#: sc-398713,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3094545">AB_3094545</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ATP5a (Mouse monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#: ab14748,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_301447">AB_301447</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-TOMM20 (Rat monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#: Ab289670,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3097753">AB_3097753</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-GFP (Chicken polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#: Ab13970,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_300798">AB_300798</ext-link></td><td align="left" valign="top">WB (1:1000)<break/>IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-rabbit HRP (Goat polyclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: G21234,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2536530">AB_2536530</ext-link></td><td align="left" valign="top">WB (1:5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-mouse HRP (Goat polyclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: PI31430,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_228307">AB_228307</ext-link></td><td align="left" valign="top">WB (1:5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Goat polyclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: A32723,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2633275">AB_2633275</ext-link></td><td align="left" valign="top">IF (1:300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 633 (Goat polyclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: A21071,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2535732">AB_2535732</ext-link></td><td align="left" valign="top">IF (1:300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 (Goat polyclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: A11036,<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10563566">AB_10563566</ext-link></td><td align="left" valign="top">IF (1:300)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA3.1+/C-(K)-DYK-ATP5F1A</td><td align="left" valign="top">Made by GenScript</td><td align="left" valign="top">Clone ID: OHu25769D</td><td align="left" valign="top">Construct to express human ATP5F1A. Available from Wu Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA3.1+/C-(K)-DYK-ATP5F1A-AT3</td><td align="left" valign="top">Made by GenScript</td><td align="left" valign="top">Modified from OHu25769D</td><td align="left" valign="top">Construct to express human ATP5F1A with AT3 tail. Available from Wu Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA3.1+/C-(K)-DYK-ATP5F1A-AT20</td><td align="left" valign="top">Made by GenScript</td><td align="left" valign="top">Modified from OHu25769D</td><td align="left" valign="top">Construct to express human ATP5F1A with AT20 tail. Available from Wu Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA3.1+/C-(K)-DYK-ATP5F1A-GS3</td><td align="left" valign="top">Made by GenScript</td><td align="left" valign="top">Modified from OHu25769D</td><td align="left" valign="top">Construct to express human ATP5F1A with GS3 tail. Available from Wu Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA3.1+/C-(K)-ATP5F1A-DYK-GS20</td><td align="left" valign="top">Made by GenScript</td><td align="left" valign="top">Modified from OHu25769D</td><td align="left" valign="top">Construct to express human ATP5F1A with GS20 tail. Available from Wu Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV-5×FLAG-β-globin-control</td><td align="left" valign="top">Dr. Hoshino and Dr. Inada</td><td align="left" valign="top"/><td align="left" valign="top">Available from Inada Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV-5×FLAG-β-globin-non-stop</td><td align="left" valign="top">Dr. Hoshino and Dr. Inada</td><td align="left" valign="top"/><td align="left" valign="top">Available from Inada Lab</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV6-DDK-NEMF (NM_004713)</td><td align="left" valign="top">ORIGENE</td><td align="left" valign="top">Cat#: RC216806L3</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">lonp1_F</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">TGCCTTGAACCCTCTCTAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">lonp1_R</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">TCTGCTTGATCTTCTCCTCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">mthsp70_F</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">ACTCCTCCATTTATCCGCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">mthsp70_R</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">ACCTTTGCTTGTTTACCTTCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">hsp60_F</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">ACCTGCTCTTGAAATTGCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">hsp60_R</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">CAATCCCTCTTCTCCAAACAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">actb_F</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">TGTTTGAGACCTTCAACACC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">actb_R</td><td align="left" valign="top">Made by GeneWiz</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top"><named-content content-type="sequence">ATGTCACGCACGATTTCC</named-content></td></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">AGM SingleQuots Supplements</td><td align="left" valign="top">Lonza</td><td align="left" valign="top">Cat#: CC-4123</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">MTT assay kit</td><td align="left" valign="top">Roche</td><td align="left" valign="top">Cat#: 11465007001</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Seahorse Cell Mito Stress Test kit</td><td align="left" valign="top">Agilent</td><td align="left" valign="top">Cat#: 103010-100</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">NativePAGE Running Buffer Kit</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: BN2007</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">NativePAGE Sample Prep Kit</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: BN2008</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">TUNEL assay</td><td align="left" valign="top">ApexBio</td><td align="left" valign="top">Cat#: K1134</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Annexin V-FITC/PI apoptosis assay</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat#: 640914</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Seahorse XF DMEM medium</td><td align="left" valign="top">Agilent</td><td align="left" valign="top">Cat#: 103575-100</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Mitochondrial Transition Pore Assay</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: I35103</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">DMEM</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">Cat#: 302002</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">FBS</td><td align="left" valign="top">Biowest</td><td align="left" valign="top">Cat#: S1620-100</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Penicillin/streptomycin</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 15140122</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">G418</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 10131027</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">0.25% trypsin solution</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">Cat#: SM2003C</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">ABM Basal Medium</td><td align="left" valign="top">Lonza</td><td align="left" valign="top">Cat#: CC-3187</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Accutase</td><td align="left" valign="top">Corning</td><td align="left" valign="top">Cat#: 25058CI</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Neural basal-A Medium</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 10888022</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">B27</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 17504044</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">N2</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 17502048</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">EGF and FGF</td><td align="left" valign="top">Shenandoah Biotech</td><td align="left" valign="top">Cat#: PB-500-017</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Antibiotic-Antimycotic</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 15240062</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">L-Glutamine</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">Cat#: 250300810</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Geltrex</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: A1413202</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">X-tremeGENE</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">Cat#: 6366244001</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Anisomycin</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: AAJ62964MF</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Cycloheximide</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: AC357420010</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Temozolomide</td><td align="left" valign="top">Millipore Sigma</td><td align="left" valign="top">Cat#: 50-060-90001</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Formaldehyde</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: BP531-500</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Triton X-100</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: T9284</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Lipofectamine 3000</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: L3000015</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Normal goat serum</td><td align="left" valign="top">Jackson Immuno</td><td align="left" valign="top">Cat#: 005-000-121</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">DAPI</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: 57-481-0</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Fluoromount-G Anti-Fade</td><td align="left" valign="top">Southern Biotech</td><td align="left" valign="top">Cat#: 0100-35</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Puromycin</td><td align="left" valign="top">ARCOS organics</td><td align="left" valign="top">Cat#: 227420100</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Protease inhibitor</td><td align="left" valign="top">Bimake</td><td align="left" valign="top">Cat#: B14002</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Bradford</td><td align="left" valign="top">BioVision</td><td align="left" valign="top">Cat#: K813-5000-1</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Mannitol</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: AA3334236</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Sucrose</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: AA36508A1</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">HEPES</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: 15630106</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Western Lightning Plus-ECL</td><td align="left" valign="top">PerkinElmer Inc</td><td align="left" valign="top">Cat#: NEL104001EA</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">4–12% Tris-Glycine gel</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: WXP41220BOX</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">PVDF membrane</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">Cat#: ISEQ00010</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">EGTA</td><td align="left" valign="top">Fisher Scientific</td><td align="left" valign="top">Cat#: 28-071G</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Digitonin</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: BN2006</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">G-250</td><td align="left" valign="top">GoldBio</td><td align="left" valign="top">Cat#: C-460-5</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">3–12% Bis-Tris Native gel</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: BN1001BOX</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Acetic acid</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: 9526-33</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">TMRM</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: I34361</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">JC-10</td><td align="left" valign="top">AdipoGen</td><td align="left" valign="top">Cat#: 50-114-6552</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Succinate</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: 041983.A7</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Hank’s Balanced Salt Solution</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: 14025092</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Calcium Green-5N</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: C3737</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Cyclosporine A</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: AC457970010</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Ethanol</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">Cat#: R40135</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Crystal violet</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">Cat#: V5265</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Proteinase K</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: 25530049</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical Compound, drug</td><td align="left" valign="top">Caspase-3/7 detection reagents</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: C10432</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">ATP-red dye</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">Cat#: SCT045</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">MitoTracker-Green</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: M7514</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Protein A/G magnetic beads</td><td align="left" valign="top">Pierce</td><td align="left" valign="top">Cat#: 88802</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">M.O.M. blocking reagent</td><td align="left" valign="top">Vector Laboratories</td><td align="left" valign="top">Cat#: BMK-2202</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">SPSS</td><td align="left" valign="top">SPSS</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002865">SCR_002865</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">GraphPad Prism 9.4.1</td><td align="left" valign="top">GraphPad</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">ImageJ 1.53t</td><td align="left" valign="top">NIH</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/download.html">https://imagej.nih.gov/ij/download.html</ext-link></td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">ZEN (blue edition)</td><td align="left" valign="top">ZEISS</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_013672">SCR_013672</ext-link></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.zeiss.com/microscopy/us/products/microscope-software.html">https://www.zeiss.com/microscopy/us/products/microscope-software.html</ext-link></td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Gen5</td><td align="left" valign="top">Agilent Technologies (BioTek)</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_017317">SCR_017317</ext-link></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.biotek.com/products/software-robotics-software/gen5-microplate-reader-and-imager-software/">https://www.biotek.com/products/software-robotics-software/gen5-microplate-reader-and-imager-software/</ext-link></td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Endnote 20</td><td align="left" valign="top">Clarivate</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014001">SCR_014001</ext-link></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://endnote.com/downloads">https://endnote.com/downloads</ext-link></td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99438.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sugimura</surname><given-names>Rio</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The University of Hong Kong</institution><country>Hong Kong</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>Glioblastoma is among the most aggressive cancers without a cure, and its cells are characterized by high mitochondrial membrane potential. This manuscript provides <bold>convincing</bold> evidence that glioblastoma tumorigenesis is closely linked to mitochondrial stress. The study makes a <bold>valuable</bold> contribution to the field by advancing our understanding of the metabolic mechanisms driving glioblastoma and highlighting potential therapeutic targets.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99438.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Cai et al have investigated the role of msiCAT-tailed mitochondrial proteins that frequently exist in glioblastoma stem cells. Overexpression of msiCAT-tailed mitochondrial ATP synthase F1 subunit alpha (ATP5) protein increases the mitochondrial membrane potential and blocks mitochondrial permeability transition pore formation/opening. These changes in mitochondrial properties provide resistance to staurosporine (STS)-induced apoptosis in GBM cells. Therefore, msiCAT-tailing can promote cell survival and migration, while genetic and pharmacological inhibition of msiCAT-tailing can prevent the overgrowth of GBM cells.</p><p>Strengths:</p><p>The CATailing concept has not been explored in cancer settings. Therefore, the present provides new insights for widening the therapeutic avenue.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99438.4.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This work explores the connection between glioblastoma, mito-RQC, and msiCAT-tailing. They build upon previous work concluding that ATP5alpha is CAT-tailed and explore how CAT-tailing may affect cell physiology and sensitivity to chemotherapy. The authors conclude that when ATP5alpha is CAT-tailed, it either incorporates into the proton pump or aggregates and that these events dysregulate MPTP opening and mitochondrial membrane potential and that this regulates drug sensitivity. This work includes several intriguing and novel observations connecting cell physiology, RQC, and drug sensitivity. This is also the first time this reviewer has seen an investigation of how a CAT tail may specifically affect the function of a protein.</p><p>Comment from the Reviewing Editor:</p><p>The revisions made the work more valuable and convincing. The authors adequately made point-by-point response to the reviewers comments by providing new data. Image acquisition and data analysis were further clarified. NEMF knockdown experiments and additional control data for ATP5α featuring a poly-glycine-serine (GS) tail support their conclusion.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99438.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bei</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Ting</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Reddy</surname><given-names>Esha</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yuanna</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Mondal</surname><given-names>Isha</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yinglu</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gbufor</surname><given-names>Adaeze Scholastical</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jerry</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Yawei</given-names></name><role specific-use="author">Author</role><aff><institution>Clemson University</institution><addr-line><named-content content-type="city">Clemson</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qing</given-names></name><role specific-use="author">Author</role><aff><institution>Clemson University</institution><addr-line><named-content content-type="city">Clemson</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Raymond</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Winson S</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Rongze Olivia</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Zhihao</given-names></name><role specific-use="author">Author</role><aff><institution>Southern Methodist University</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife Assessment:</bold></p><p>Glioblastoma is one of the most aggressive cancers without a cure. Glioblastoma cells are known to have high mitochondrial potential. This useful study demonstrates the critical role of the ribosome-associated quality control (RQC) pathway in regulating mitochondrial membrane potential and glioblastoma growth. Some assays are incomplete; further revision will improve the significance of this study.</p></disp-quote><p>For clarity, we propose revising the second sentence to: &quot;It is well-established that certain cancer cells, such as glioblastoma cells, exhibit elevated mitochondrial membrane potential.&quot;</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>Cai et al have investigated the role of msiCAT-tailed mitochondrial proteins that frequently exist in glioblastoma stem cells. Overexpression of msiCAT-tailed mitochondrial ATP synthase F1 subunit alpha (ATP5) protein increases the mitochondrial membrane potential and blocks mitochondrial permeability transition pore formation/opening. These changes in mitochondrial properties provide resistance to staurosporine (STS)-induced apoptosis in GBM cells. Therefore, msiCAT-tailing can promote cell survival and migration, while genetic and pharmacological inhibition of msiCAT-tailing can prevent the overgrowth of GBM cells.</p><p>Strengths:</p><p>The CAT-tailing concept has not been explored in cancer settings. Therefore, the present provides new insights for widening the therapeutic avenue.</p></disp-quote><p>Your acknowledgment of our study's pioneering elements is greatly appreciated.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Although the paper does have strengths in principle, the weaknesses of the paper are that these strengths are not directly demonstrated. The conclusions of this paper are mostly well-supported by data, but some aspects of image acquisition and data analysis need to be clarified and extended.</p></disp-quote><p>We are grateful for your acknowledgment of our study’s innovative approach and its possible influence on cancer therapy. We sincerely appreciate your valuable feedback. In response, this updated manuscript presents substantial new findings that reinforce our central argument. Moreover, we have broadened our data analysis and interpretation, as well as refined our methodological descriptions.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>This work explores the connection between glioblastoma, mito-RQC, and msiCAT-tailing. They build upon previous work concluding that ATP5alpha is CAT-tailed and explore how CAT-tailing may affect cell physiology and sensitivity to chemotherapy. The authors conclude that when ATP5alpha is CAT-tailed, it either incorporates into the proton pump or aggregates and that these events dysregulate MPTP opening and mitochondrial membrane potential and that this regulates drug sensitivity. This work includes several intriguing and novel observations connecting cell physiology, RQC, and drug sensitivity. This is also the first time this reviewer has seen an investigation of how a CAT tail may specifically affect the function of a protein. However, some of the conclusions in this work are not well supported. This significantly weakens the work but can be addressed through further experiments or by weakening the text.</p></disp-quote><p>We appreciate the recognition of our study's novelty. To address your concerns about our conclusions, we have revised the manuscript. This revision includes new data and corrections of identified issues. Our detailed responses to your specific points are outlined below.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) In Figure 1B, please replace the high-exposure blots of ATP5 and COX with representative results. The current results are difficult to interpret clearly. Additionally, it would be helpful if the author could explain the nature of the two different bands in NEMF and ANKZF1. Did the authors also examine other RQC factors and mitochondrial ETC proteins? I'm also curious to understand why CAT-tailing is specific to C-I30, ATP5, and COX-V, and why the authors did not show the significance of COX-V.</p></disp-quote><p>We appreciate your inquiry regarding the data. Additional attempts were made using new patient-derived samples; however, these results did not improve upon the existing ATP5⍺, (NDUS3)C-I30, and COX4 signals presented in the figure. This is possibly due to the fact that CAT-tail modified mitochondrial proteins represent only a small fraction of the total proteins in these cells. It is acknowledged that the small tails visible above the prominent main bands are not particularly distinct. To address this, the revised version includes updated images to better illustrate the differences. We believe the assertion that GBM/GSCs possess CAT-tailed proteins is substantiated by a combination of subsequent experimental findings. The figure (refer to new Fig. 1B) serves primarily as an introduction. It is important to note that the CAT-tailed ATP5⍺ plays a vital role in modulating mitochondrial potential and glioma phenotypes, a function which has been demonstrated through subsequent experiments.</p><p>It is acknowledged that the CAT-tail modification is not exclusive to the ATP5⍺protein. ATP5⍺ was selected as the primary focus of this study due to its prevalence in mitochondria and its specific involvement in cancer development, as noted by Chang YW et al. Future research will explore the possibility of CAT tails on other mitochondrial ETC proteins. Currently, NDUS3 (C-I30), ATP5⍺, and COX4 serve as examples confirming the existence of these modifications. It remains challenging to detect endogenous CAT-tailing, and bulk proteomics is not yet feasible for this purpose. COX4 is considered significant. We hypothesize that CAT-tailed COX4 may function similarly to the previously studied C-I30 (Wu Z, et al), potentially causing substantial mitochondrial proteostasis stress.</p><p>Concerning RQC proteins, our blotting analysis of GBM cell lines now includes additional RQC-related factors. The primary, more prominent bands (indicated by arrowheads) are, in our assessment, the intended bands for NEMF and ANKZF1. Subsequent blotting analyses showed only single bands for both ANKZF1 and NEMF, respectively. The additional, larger molecular weight band of NEMF, which was initially considered for property analysis (phosphorylation, ubiquitination, etc.), was not examined further as it did not appear in subsequent experiments (refer to new Fig. S1C).</p><p>References:</p><p>Chang YW, et al. Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface. Communications biology. 2023;6(1).</p><p>Wu Z, et al. MISTERMINATE Mechanistically Links Mitochondrial Dysfunction With Proteostasis Failure. Molecular cell. 2019;75(4).</p><disp-quote content-type="editor-comment"><p>(2) In addition to Figure 1B, it would be interesting to explore CAT-tailed mETC proteins in cancer tissue samples.</p></disp-quote><p>This is an excellent point, and we appreciate the question. We conducted staining for ATP5⍺ and key RQC proteins in both tumor and normal mouse tissues. Notably, ATP5⍺ in GBM exhibited a greater tendency to form clustered punctate patterns compared to normal brain tissue, and not all of it co-localized with the mitochondrial marker TOM20 (refer to new Fig. S3C-E). Crucially, we observed a significant increase in NEMF expression within mouse xenograft tumor tissues, alongside a decrease in ANKZF1 expression (refer to new Fig. S1A, B). These findings align with our observations in human samples.</p><disp-quote content-type="editor-comment"><p>(3) Please knock down ATP5 in the patient's cells and check whether both the upper band and lower band of ATP5 have disappeared or not.</p></disp-quote><p>This control was essential and has been executed now. To validate the antibody's specificity, siRNA knockdown was performed. The simultaneous elimination of both upper and lower bands upon siRNA treatment (refer to new Fig. S2A) confirms they represent genuine signals recognized by the antibody.</p><disp-quote content-type="editor-comment"><p>(4) In Figure 1C and ID, add long exposure to spot aggregation and oligomer. Figure 1D, please add the blots where control and ATP5 are also shown in NHA and SF (similar to SVG and GSC827).</p></disp-quote><p>New data are included in the revised manuscript to address the queries. Specifically, the new Fig 1D now displays the full queue as requested, featuring blots for Control, ATP5α, AT3, and AT20. Our analysis reveals that AT20 aggregates exhibit higher expression and accumulation rates in GSC and SF cells.</p><p>Fig. 1C has been updated to include experimental groups treated with cycloheximide and sgNEMF. Our results show that sgNEMF effectively inhibits CAT-tailing in GBM cell lines, whereas cycloheximide has no impact. After consulting with the Reporter's original creator and optimizing expression conditions, we observed no significant aggregates with β-globin-non-stop protein, potentially due to the length of endogenous CAT-tail formation (as noted by Inada, 2020, in Cell Reports). Our analysis focused on the ratio of CAT-tailed (red box blots) and non-CAT-tailed proteins (green box blots). Comparing these ratios revealed that both anisomycin treatment and sgNEMF effectively hinder the CAT-tailing process, while cycloheximide has no effect.</p><disp-quote content-type="editor-comment"><p>(5) In Figure 1E, please double-check the results with the figure legend. ATP5A aggregated should be shown endogenously. The number of aggregates shown in the bar graph is not represented in micrographs. Please replace the images. For Figure 1E, to confirm the ATP5-specific aggregates, it would be better if the authors would show endogenous immunostaining of C-130 and Cox-IV.</p></disp-quote><p>Labels in Fig. 1E were corrected to reflect that the bar graph in Fig. 1F indicates the number of cells with aggregates, not the quantity of aggregates per cell. The presence</p><disp-quote content-type="editor-comment"><p>(6) Figure 3A. Please add representative images in the anisomycin sections. It is difficult to address the difference.</p></disp-quote><p>We appreciate your feedback. Upon re-examining the Calcein fluorescence intensity data in Fig. 3A, we believe the images accurately represent the statistical variations presented in Fig. 3B. To address your concerns more effectively, please specify which signals in Fig. 3A you find potentially misleading. We are prepared to revise or substitute those images accordingly.</p><disp-quote content-type="editor-comment"><p>(7) Figure 3D. If NEMF is overexpressed, is the CAT-tailing of ATP 5 reversed?</p></disp-quote><p>Thank you. Your prediction aligns with our findings. We've added data to the revised Fig. S6A, B, which demonstrates that both NEMF overexpression and ANKZF1 knockdown lead to elevated levels of CRC. This increase, however, was not statistically significant in GSC cells. A plausible explanation for this discrepancy is that the MPTP of GSC cells is already closed, thus any additional increase in CAT-tailing activity does not result in further amplification.</p><disp-quote content-type="editor-comment"><p>(8) Figure 3G. Why on the BN page are AT20 aggregates not the same as shown in Figure 2E?</p></disp-quote><p>We appreciate your inquiry regarding the ATP5⍺ blots, specifically those in the original Fig. 3G (left) and 2E (right). Careful observation of the ATP5⍺ band placement in these figures reveals a high degree of similarity. Notably, there are aggregates present at the top, and the diffuse signals extend downwards. Given that this is a gradient polyacrylamide native PAGE, the concentration diminishes towards the top. Consequently, the non-rigid nature of the Blue Native PAGE gel may lead to slight variations in the aggregate signals; however, the overall patterns are very much alike. To mitigate potential misinterpretations, we have rearranged the blot order in the new Fig. 3M.</p><disp-quote content-type="editor-comment"><p>(9) Figure 4D. The amount of aggregation mediated by AT20 is more compared to AT3. Why are there no such drastic effects observed between AT3 and AT20 in the Tunnel assay?</p></disp-quote><p>The previous Figure 4D presents the quantification of cell migration from the experiment depicted in Figure 4C. But this is a good point. TUNEL staining results are directly influenced by mitochondrial membrane potential and the state of mitochondrial permeability transition pores</p><p>(MPTP), not by the degree of protein aggregation. Our previous experiments showed comparable effects of AT3 and AT20 on mitochondria (Fig. 2E, 3K), which aligns with the expected similar outcomes on TUNEL staining. As for its biological nature, this could be very complicated. We hope to explore it in future studies.</p><disp-quote content-type="editor-comment"><p>(10) Figure 5C: The role of NEMF and ANKZF1 can be further clarified by conducting Annexin-PI assays using FACS. The inclusion of these additional data points will provide more robust evidence for CAT-tailing's role in cancer cells.</p></disp-quote><p>In response to your suggestion, we have incorporated additional data into the revised version.Using the Annexin-PI kit, we labeled apoptotic cells and detected them using flow cytometry (FACS). Our findings indicate that anisomycin pretreatment, NEMF knockdown (sgNEMF), and ANZKF1 upregulation (oeANKZF1) significantly increase the rate of STS-induced apoptosis compared to the control group (refer to new Fig. S9D-G).</p><disp-quote content-type="editor-comment"><p>(11) Figure 5F: STS is a known apoptosis inhibitor. Why it is not showing PARP cleavage? Also, cell death analysis would be more pronounced, if it could be shown at a later time point. What is the STS and Anisomycin at 24h or 48h time-point? Since PARP is cleaved, it would also be better if the authors could include caspase blots.</p></disp-quote><p>I guess what you meant to say here is &quot;Staurosporine is a protein kinase inhibitor that can induce apoptosis in multiple mammalian cell lines.&quot; Our study observed PARP cleavage even in GSCs, which are typically more resistant to staurosporine-induced apoptosis (C-PARP in Fig. S9B). The ratio of C-PARP to total PARP increased. We selected a 180-minute treatment duration because longer treatments with STS + anisomycin led to a late stage of apoptosis and non-specific protein degradation (e.g., at 24 or 48 hours), making PARP comparisons less meaningful. Following your suggestion, we also examined caspase 3/7 activity in GSC cells treated with DMSO, CHX, and anisomycin. We found that anisomycin treatment also activated caspases (Fig. S9A).</p><disp-quote content-type="editor-comment"><p>(12) In Figure 5, the addition of an explanation, how CAT-tailing can induce cell death, would add more information such as BAX-BCL2 ratio, and cytochrome-c release from the mitochondria.</p></disp-quote><p>Thank you for your suggestion. In this study, we state that specific CAT-tails inhibit GSC cell death/apoptosis rather than inducing it. Therefore, we do not expect that examining BAX-BCL2 and mitochondrial cytochrome c release would offer additional insights.</p><disp-quote content-type="editor-comment"><p>(13) To confirm the STS resistance, it would be better if the author could do the experiments in the STS-resistant cell line and then perform the Anisomycin experiments.</p></disp-quote><p>Thank you. We should emphasize that our data primarily originates from GSC cells. These cells already exhibit STS-resistance when compared to the control cells (Fig. S8A-C).</p><disp-quote content-type="editor-comment"><p>(14) It would be more advantageous if the author could show ATP5 CATailed status under standard chemotherapy conditions in either cell lines or in vivo conditions.</p></disp-quote><p>This is an interesting question. It's worth exploring this question; however, GSC cells exhibit strong resistance to standard chemotherapy treatments like temozolomide (TMZ).</p><p>Additionally, we couldn't detect changes in CAT-tailed ATP5⍺ and thus did not include that data.</p><disp-quote content-type="editor-comment"><p>(15) In vivo (cancer mouse model or cancer fly model) data will add more weight to the story.</p></disp-quote><p>We appreciate your intriguing question. An effective approach would be to test the RQC pathway's function using the Drosophila Notch overexpression-induced brain tumor model. However, Khaket et al. have conducted similar studies, stating, &quot;The RNAi of Clbn, VCP, and Listerin (Ltn), homologs of key components of the yeast RQC machinery, all attenuated NSC over-proliferation induced by Notch OE (Figs. 5A and S5A–D, G).&quot; This data supports our theory, and we have incorporated it into the Discussion. While the mouse model more closely resembles the clinical setting, it is not covered by our current IACUC proposal. We intend to verify this hypothesis in a future study.</p><p>Reference:</p><p>Khaket TP, Rimal S, Wang X, Bhurtel S, Wu YC, Lu B. Ribosome stalling during c-myc translation presents actionable cancer cell vulnerability. PNAS Nexus. 2024 Aug 13;3(8):pgae321.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Figure 1B, C: To demonstrate that Globin, ATP5alpha, and C-130 are CAT-tailed, it is necessary to show that the high mobility band disappears after NEMF deletion or mutagenesis of the NFACT domain of NEMF. This can be done in a cell line. The anisomycin experiment is not convincing because the intensity of the bands drops and because no control is done to show that the effects are not due to translation inhibition (e.g. cycloheximide, which inhibits translation but not CAT tailing). Establishing ATP5alpha as a bonafide RQC substrate and CAT-tailed protein is critical to the relevance of the rest of the paper.</p></disp-quote><p>Thank you for suggesting this crucial control experiment. To confirm the observed signal is indeed a bona fide CAT-tail, it's essential to demonstrate that NEMF is necessary for the CAT-tailing process. We have incorporated data from NEMF knockdown (sgNEMF) and cycloheximide treatment into the revised manuscript. Our findings show that both sgNEMF and anisomycin treatment effectively inhibit the formation of CAT-tailing signals on the reporter protein (Fig. 1C). Similarly, NEMF knockdown in a GSC cell line also effectively eliminated CAT-tails on overexpressed ATP5⍺ (Fig. S2B).</p><disp-quote content-type="editor-comment"><p>In general, the text should be weakened to reflect that conclusions were largely gleaned from artificial CAT tails made of AT repeats rather than endogenously CAT-tailed ATP5alpha. CAT tails could have other sequences or be made of pure alanine, as has been suggested by some studies.</p></disp-quote><p>Thank you for your reminder. We have reviewed the recent studies by Khan et al. and Chang et al., and we found their analysis of CAT tail components to be highly insightful. We concur with your suggestion regarding the design of the CAT tail sequence. We aimed to design a tail that maintained stability and resisted rapid degradation, regardless of its length. In the revised version, we clarify that our conclusions are based on artificial CAT tails, specifically those composed of AT repeat sequences (p. 9). We acknowledge that the presence of other sequence components may lead to different outcomes (p. 19).</p><p>Reference:</p><p>Khan D, Vinayak AA, Sitron CS, Brandman O. Mechanochemical forces regulate the composition and fate of stalled nascent chains. bioRxiv [Preprint]. 2024 Oct 14:2024.08.02.606406. Chang WD, Yoon MJ, Yeo KH, Choe YJ. Threonine-rich carboxyl-terminal extension drives aggregation of stalled polypeptides. Mol Cell. 2024 Nov 21;84(22):4334-4349.e7.</p><disp-quote content-type="editor-comment"><p>Throughout the work (e.g. 3B, C), anisomycin effects should be compared to those with cycloheximide to observe if the effects are specific to a CAT tail inhibitor rather than a translation inhibitor.</p></disp-quote><p>We agree that including cycloheximide control experiments is crucial. The revised version now incorporates new data, as depicted in Fig. S5A, B, illustrating alterations in the on/off state of MPTP following cycloheximide treatment. Furthermore, Fig. S6A, B present changes in Calcium Retention Capacity (CRC) under cycloheximide treatment. The consistency of results across these experiments, despite cycloheximide treatment, suggests that anisomycin's role is specifically as a CAT tail inhibitor, rather than a translation inhibitor.</p><disp-quote content-type="editor-comment"><p>Line 110, it is unclear what &quot;short-tailed ATP5&quot; is. Do you mean ATP5alpha-AT3? If so this needs to be introduced properly. Line 132: should say &quot;may indicate accumulation of CAT-tailed protein&quot; rather than &quot;imply&quot;.</p></disp-quote><p>We acknowledge your points. We have clarified that the &quot;short-tailed ATP5α&quot; refers to ATP5α-AT3 and incorporated the requested changes into the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Figure 1C: how big are those potential CAT-tails (need to be verified as mentioned earlier)?They look gigantic. Include a ladder.</p></disp-quote><p>In the revised Fig. 1D, molecular weight markers have been included to denote signal sizes. The aggregates in the previous Fig. 1C, also present in the control plasmid, are likely a result of signal overexposure. The CAT-tailed protein is observed just above the intended band in these blots. These aggregates have been re-presented in the updated figures, and their signal intensities quantified.</p><disp-quote content-type="editor-comment"><p>Line 170: &quot;indicating that GBM cells have more capability to deal with protein aggregation&quot;. This logic is unclear. Please explain.</p></disp-quote><p>We appreciate your question and have thoroughly re-evaluated our conclusion. We offer several potential explanations for the data presented in Fig. 1D: (1) ATP5α-AT20 may demonstrate superior stability. (2) GSC (GBM) cells might lack adequate mechanisms to monitor protein accumulation. (3) GSC (GBM) cells could possess an increased adaptive capacity to the toxicity arising from protein accumulation. This discussion has been incorporated into the revised manuscript (lines 166-169).</p><disp-quote content-type="editor-comment"><p>Line 177: how do you know the endogenous ATP5alpha forms aggregates due to CAT-tailing? Need to measure in a NEMF hypomorph.</p></disp-quote><p>We understand your concern and have addressed it. Revised Fig. 3G, H demonstrates that a reduction in NEMF levels, achieved through sgNEMF in GSC cells, significantly diminishes ATP5α aggregation. This, in conjunction with the Anisomycin treatment data presented in revised Fig. 3E, F, confirms the substantial impact of the CAT-tailing process on this aggregation.</p><disp-quote content-type="editor-comment"><p>Line 218: really need a cycloheximide or NEMF hypomorph control to show this specific to CAT-tailing.</p></disp-quote><p>We have revised the manuscript to include data from sgNEMF and cycloheximide treatments, specifically Fig. 3G, H, and Fig. S5C, D, as detailed in our response above.</p><disp-quote content-type="editor-comment"><p>Lines 249,266, Figure 5A: The mentioned experiments would benefit from controls including an extension of ATP5alpha that was not alanine and threonine, perhaps a gly-ser linker, as well as an NEMF hypomorph.</p></disp-quote><p>We sincerely appreciate your insightful comments. In response, the revised manuscript now incorporates control data for ATP5α featuring a poly-glycine-serine (GS) tail. This data is specifically presented in Figs. S2E-G, S4E, S7A, D, E, and S8F, G. Our experimental findings consistently demonstrate that the overexpression of ATP5α, when modified with GS tails, had no discernible impact on protein aggregation, mitochondrial membrane potential, GSC cell mobility, or any other indicators assessed in our study.</p><disp-quote content-type="editor-comment"><p>Figure S5A should be part of the main figures and not in the supplement.</p></disp-quote><p>This has been moved to the main figure (Fig. 5C).</p></body></sub-article></article>